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I NTRODUCTION
This paper examines the current literature and policy implications of substance use and substance
use disorders among pregnant and parenting women. While this is not meant to serve as an
exhaustive literature review on this topic, it seeks to describe: current research on health effects of
substance use and substance use disorders on pregnant women1 and their children; policies and
programs that help ensure that pregnant women who use substances have access to the highest
quality healthcare, including prenatal care; the current barriers to accessing treatment for substance
use disorders for pregnant women, including those who are incarcerated; and the impact of laws and
policies regarding substance use on pregnant women and families.
Strong evidence exists about the harmful effects of certain kinds of substance use, such as heavy
drinking and smoking, while pregnant. Less is known about the maternal and fetal effects of
moderate alcohol intake or of some other individual substances, such as cannabis, and it is difficult
to develop a strong evidence base on their effects. It would be unethical for researchers to ask study
participants to take drugs while pregnant in order to study their impacts, and it is challenging to
attribute outcomes to specific drugs when so many women who use substances are using multiple
substances simultaneously and also facing poverty, violence, and other known risk factors for poor
health outcomes. Yet policies addressing substance use often assume that any and all substance use
during pregnancy is harmful and establish harsh penalties that can discourage women who need
treatment from receiving it, as well as create barriers to other services that could improve the health
and well-being of pregnant and parenting women and their families. Thus, it is important to examine
current research in this area and to create policies based on such research.
In the United States, policies regarding substance use have often developed in the absence of
complete knowledge or appropriate consideration of the likely negative outcomes of criminalization.
For example, when the Eighteenth Amendment instituted a prohibition on the production and sale
of alcohol in 1920, lawmakers’ intent was to decrease dangerous behavior that accompanied
consumption of alcohol, but the next decade saw the development of a substantial black market for
alcohol and a concomitant increase in organized crime. After just over a decade, the federal
government reversed the policy in light of these unanticipated consequences. In modern times, a
growing number of policymakers, advocates, and scholars have declared the country’s current efforts
to prohibit use of specific drugs a failure, as the toll from drug-trafficking violence has climbed and
harsh penalties have fallen disproportionately on poor and minority drug users. Additionally,
research has found that some drugs, such as cannabis, are associated with moderate benefits, and
many states have decriminalized, and even legalized, cannabis use.
In contrast to punitive measures, a public health approach to substance use emphasizes harm
reduction and treatment. It recognizes that, while substance use may have negative consequences,

1 For simplicity, we use “pregnant women” throughout this paper to refer to those who are, or are biologically
capable of becoming, pregnant. This may include individuals who do not identify as women.
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imposing legal punishments on people with substance use disorders often leads to worse outcomes.
It considers the sociocultural and neurological factors that put some populations at risk of substance
use disorder and exacerbate substances’ toll. Such a public health approach is especially important
when addressing substance use disorder in women who are pregnant. Effective treatment can set
women and their infants on a path to better health, while punitive approaches – including charging
women with child abuse for using substances while pregnant, and/or removing their children from
them – can create trauma and stress as well as barriers that make it less likely women will receive any
healthcare services, including not only treatment for substance use itself but also other services that
benefit maternal and infant health, such as prenatal care.

S UBSTANCE U SE D ISORDERS

AND

P REGNANT W OMEN

Not all substance use is problematic. For example, alcohol in moderation can be beneficial, whereas
years of heavy drinking may cause substantial health damage, and driving while intoxicated is a major
public health hazard. However, substance use disorders can have both long- and short-term impacts
on the health of women and families.
The diagnostic criteria for substance use disorders2 (SUDs) address impaired control, social
impairment, risky use, tolerance, and withdrawal, and patients may be diagnosed with mild, moderate,
or severe SUD depending on the number of criteria they meet (American Psychiatric Association
[APA], 2013). (See Box 1 for more details.) Approximately 8% of U.S. individuals have a substance
use disorder (Substance Abuse and Mental Health Services Administration [SAMHSA], 2014a).
To address substance use disorder appropriately, it is useful to understand how addictive drugs
affect the human brain. Addiction is a chronic disease of the brain, and develops as repeated drug
administration triggers changes to portions of the brain involved with rewards and impulsivity.
These changes make people’s brains respond more to drug cues and less to non-drug rewards, while
increasing sensitivity to stressful stimuli and weakening the ability to self-regulate (Volkow &
Morales, 2015). Such changes make it especially difficult to stop using substances, even when people
recognize the harmful effects of continued use.
Research has consistently found strong associations between substance use disorders and other
mental health conditions, particularly anxiety and depression (Jane-Llopis & Matytsina, 2006). In the
U.S., those with SUDs are up to 4.5 times more likely to also receive a diagnosis of another
psychiatric disorder, compared to those without SUDs (Chen et al., 2011). Services for these cooccurring disorders are a recommended component of substance abuse treatment (SAMHSA, 2009).

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) uses the term “substance use
disorders” (SUD) rather than “substance abuse” or “substance dependence,” which both appeared in the previous
edition of the DSM (Wisner, Sit, Altemus, et al., 2017).
2
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Studies have found that between one- and two-thirds of women diagnosed with a substance use
disorder had histories of childhood physical and/or sexual assault. Among women with substance
use disorders, studies have found that 30-59% had post-traumatic stress disorder (PTSD), in
contrast to approximately 11% of women in the general population. For some women, substance
use may be a form of “self-medicating” in response to trauma (Najavits, Weiss, & Shaw, 1997).
Unaddressed trauma significantly increases the risk of SUD, as well as other diseases, and current
research programs are underway to develop and disseminate trauma-informed care approaches to
better serve those who have experienced trauma (SAMHSA, 2014b).
It is important to note that not all women who use substances during pregnancy have a substance
use disorder, and evidence does not support the widely held assumption that all substance use
during pregnancy carries a risk of adverse health outcomes in infants. However, use of some
substances during pregnancy, including heavy alcohol use and some prescription drugs (used as
prescribed or used illicitly), can affect a developing fetus. Pregnant women should be informed
about the potential for negative outcomes associated with substance use both during and outside of
pregnancy, without being pressured or coerced into either continuing or terminating pregnancies.
Reducing substance use can often benefit women’s long-term health as well as the health of their
infants. In fact, pregnant women are often highly motivated to stop using substances (Center for
Substance Abuse Treatment, 2009; Hull, May, Farrell-Moore, & Svikis, 2010; Jessup & Brindis,
2005), and many cease or reduce their substance use with little or no formal treatment (Jackson &
Shannon, 2013; Jessup & Brindis, 2005). However, it is important to distinguish some substance use
from a substance use disorder. Women with substance use that meets disorder criteria may find it
especially difficult to reduce or stop substance use without treatment (Terplan et al., 2012).

C RIMINALIZATION

AND

O THER P UNITIVE P OLICIES

The history of the U.S. response to crack cocaine should serve as a cautionary tale when considering
responses to the current opioid crisis and other new and ongoing SUD epidemics. In the 1980s, the
U.S. government shifted drug control efforts from health to criminal justice and focused particular
public attention on the use of crack cocaine. At the same time media outlets warned of an epidemic
of “crack babies” suffering from severe damage due to their mothers’ drug use while pregnant.
Subsequent research has debunked this myth. A 2011 meta-analysis published in JAMA concluded
“there is no convincing evidence that prenatal cocaine exposure is associated with developmental
toxic effects that are different in severity, scope, or kind from the sequelae of multiple other risk
factors” (Frank et al., 2001).
The demonization of women who used crack while pregnant resonated with the public and created
the political will to support policymakers’ efforts to impose a range of damaging policies, as Glenn
explains:
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“However devoid of empirical evidence, it was nevertheless a story of such powerful cultural
resonance that it heavily contributed to the demonization of the poor urban underclasses:
Americans who experience systemic poverty and joblessness and whose existence has never
been captured by national unemployment statistics. This demonization in turn provided
political support for increased law enforcement surveillance, an end to the Aid to Families
with Dependent Children program, racially disparate extreme mandatory minimum
sentencing legislation, and the continued support for a criminal justice approach to
addressing substance abuse that by all accounts has failed to achieve its goals.” (Glenn, 2014)
A similar dynamic is at work today with respect to policy efforts to address opioid use. Women who
use opioids while pregnant are being demonized amidst media reports on neonatal abstinence
syndrome (NAS) (Copeland, 2014; Thomson-Deveaux, 2014) – although some commenters have
noted that the depictions of mothers who used opioids in pregnancy, many of whom are White, are
not as harsh as the descriptions of the mostly African-American mothers who used crack while
pregnant (Cadet, 2012; Holloway, 2016). In this case, unlike the reporting on the effects of crack on
infant health, NAS is an identified medical condition that requires appropriate treatment when it
occurs. When treatment is available, there is good evidence that infants can recover safely and go on
to good health (Finnegan, 2016). The existence of NAS, however, can be used to justify punitive
policies that can result in women being incarcerated, forcibly detained in treatment facilities, or
losing their children. Such policies are not limited to opioid use, and stigma and the fear of such
consequences can discourage women from seeking care, including effective SUD treatment when
needed (Finkelstein, 1994; Howell, Heiser, & Harrington, 1999; Roberts & Nuru-Jeter, 2010;
Roberts & Pies, 2011; Schempf & Strobino, 2009; Stone, 2015).
Policy responses that fail to distinguish, or blur the line, between substance use and dependence risk
imposing treatment on healthy individuals (i.e., treatment may not be medically appropriate) and
violating the autonomy and legal rights of pregnant and parenting women. Similarly, responses that
fail to consider the reason a pregnant woman or parent is using the substance and what her
alternatives might be could inadvertently put the woman, her pregnancy, and her children at risk for
greater harm. Pregnant women too often find themselves caught up in controversial policy debates,
and women of color and poor women in particular are most affected by punitive state laws seeking
control over a woman’s pregnancy. These laws often backfire, discouraging effective public health
approaches and negatively affecting reproductive autonomy. A public health approach that
emphasizes treatment access and harm reduction over punitive measures improves the likelihood of
healthier outcomes for women and their children.
It is also important to consider substance use policies for pregnant women in the context of racial
discrimination that has plagued broader drug policies in the U.S. Until recently, federal penalties for
crack cocaine were 100 times harsher than those for powder cocaine (ACLU, 2007), even though
they are pharmacologically the same drug. Urban communities of color, where crack cocaine is more
common than the powder form, suffered far more severely as law enforcement targeted their
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neighborhoods disproportionately and as those convicted of crack possession served longer prison
terms than those sentenced for powder cocaine possession. These communities have borne a
disproportionate share of the misery from the war on drugs (Drug Policy Alliance, 2016). These
policies also perpetuate a vicious cycle, as those who are incarcerated and have substance use
disorders often cannot access effective treatments for their conditions.
Current efforts to address opioid-related problems have included greater recognition of the need for
treatment. Whether this change reflects lessons learned from problematic past policies or is driven by
policymakers who respond differently to the current epidemic because many of those with opioid use
disorders are White, it is a positive development and promotes a public health approach to this problem.

B OX 1. D IAGNOSING S UBSTANCE U SE D ISORDER
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) provides criteria for
diagnosing individual substance use disorders — e.g., Alcohol Use Disorder, Opioid Use
Disorder, etc. “The essential feature of a substance use disorder is a cluster of cognitive,
behavioral, and physiological symptoms indicating that the individual continues using the
substance despite significant substance-related problems,” the DSM-5 explains (APA, 2013).
The diagnosed severity of a SUD depends on how many in a list of 12 criteria a substance user
meets. Two or three symptoms indicate a mild SUD, four or five a moderate SUD, and six or
more a severe SUD. Criteria include taking the substance in larger amounts or for longer than
originally intended; making multiple unsuccessful attempts to discontinue use; failing to fulfill
major role obligations at work, school, or home due to substance use; and continuing to use the
substance “despite knowledge of having a persistent or recurrent physical or psychological
problem that is likely to have been caused or exacerbated” by the substance (APA, 2013).
The final two criteria on the list of 12 address tolerance and withdrawal, but the DSM-5 notes that
these criteria are not considered to be met for individuals using the substance under medical
supervision (APA, 2013). A person prescribed an opioid for chronic pain and experiencing
tolerance and/or withdrawal related to its use would not be considered to have a substance use
disorder unless she met other criteria.

A P UBLIC H EALTH A PPROACH : P REVENTION
It is worth considering what preventive strategies, drawing on the principles and learnings of public
health, would look like, in contrast to policies that focus on law enforcement and punishment. These
strategies could include prevention, early intervention, and treatment of substance use disorders in
women of reproductive age. A prevention approach would be designed to address root causes rather
than symptoms by developing and instituting policies and programs to help address the personal
challenges that might lead women to seek “relief” by using substances in the first place, including
the stresses of mental illness; trauma, including physical and emotional abuse; and the challenges of
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living in poverty. It would measure success in terms of improved health outcomes for individuals
and communities. The SAMHSA Continuum of Care diagram (below) illustrates a more holistic
approach to behavioral health, which spans from community health promotion through recovery.

Figure 1. Behavioral Health Continuum of Care Model. Reprinted from SAMHSA. (2016).
Prevention of Substance Abuse and Mental Illness. Retrieved from
https://www.samhsa.gov/prevention.
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O VERVIEW

OF

S UBSTANCES A DDRESSED

IN THIS

P APER

Four classes of substances will be reviewed in this paper: Stimulants such as cocaine and
methamphetamine; cannabis; opioids and opiates; and alcohol. These substances vary in their
availability, legal status, and health impact on pregnant women and their children. The studies
described in this paper only include human subjects. We review information on maternal effects and
fetal/neonatal effects for each type of substance before addressing treatment and policy approaches.
We do not discuss tobacco because extensive research on the health effects of tobacco use during
pregnancy and policy approaches to this public health concern are thoroughly reviewed elsewhere
(Banderali et al., 2015; B. D. Holbrook, 2016).

R ESEARCH C HALLENGES
Clear, accurate data on maternal and fetal effects of substance use during pregnancy can be difficult
to acquire because of ethical guidelines; criminalization of substance use, especially use while
pregnant or parenting; and the common use of self-reported data, which can be affected by stigma
and punitive policies. Pregnant women are considered a “vulnerable population” by the U.S.
Department of Health and Human Services, so research regarding pregnant women is subject to
special regulation requiring additional protection for the women. Additionally, there is an ethical
problem with asking participants to maintain use of a drug that is known to cause any kind of
negative side effect in the fetus, without seeking a less harmful alternative or making attempts to
wean or quit. The gold standard of research, a randomized controlled trial, is impossible because it
would be requiring some of the women in the study to take drugs that are presumed to harm fetuses.
Self-reported data is also very common in these studies, and this data can be inaccurate, particularly
in cases when the study participants have reason to withhold or misrepresent the behavior being
studied, as is the case with illicit drug use. For example, a pregnant woman may underreport any
drug use, fearing judgment or legal action by the researcher. One study found only a 66% agreement
between maternal reporting of drug use and positive results on meconium tests (a biological marker
of drug use during pregnancy) (ElSohly et al., 1999; Lester et al., 2001). Many studies note that
participants may be using more than one drug during their pregnancy or during the study period,
which also makes it difficult to draw conclusions about any one specific drug.
It is also important to note that the existing knowledge base about the effects of substance use
during pregnancy is limited by the kind of research that is conducted and published. Studies
designed to identify potential benefits of substance use are rarely, if ever, funded. Studies of
substance use during pregnancy that find no harm to a fetus or infant may be less likely to be
published than those identifying harms (Koren, Graham, Shear, & Einarson, 1989).
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C OCAINE

AND

M ETHAMPHETAMINE (S TIMULANTS )

Stimulants are a class of drug that includes cocaine, methamphetamine, caffeine, and some
prescription drugs. In 2014, 1.6 million people in the U.S. used stimulants for non-medical purposes
(Center for Behavioral Health Statistics and Quality, 2015a).3 In data from 2013, cocaine users began
using at an average of 20.4 years old, and methamphetamine users at 18.9 years (SAMHSA, 2014c).
Stimulants work by increasing dopamine levels in the brain (National Institute of Drug Abuse
[NIDA], 2014a). Dopamine is the chemical in the brain associated with pleasure, attention, and
movement (NIDA, 2014a). At low levels (as with prescription medication), the increased dopamine
can be beneficial, and can be used to treat ADHD, obesity, or asthma. The low levels mimic the
slow release of dopamine that occurs naturally in the human body.
At higher levels (as with stimulants taken for non-medical or recreational purposes), the high levels
of dopamine can cause euphoria, increased energy, confidence, and arousal (NIDA, 2014a;
SAMHSA, 2016d). The higher doses may lead to negative drug effects, including increased heart
rate, increased blood pressure, increased body temperature, decreased hunger, irregular heartbeat,
and even seizures (SAMHSA, 2016c).
Cocaine is a nervous system stimulant derived from the coca plant. Cocaine powder can be snorted
or it may be dissolved into water and injected. “Crack” cocaine is smoked. Methamphetamine is
another powerful stimulant drug typically made in illegal laboratories using combinations of other
stimulants and household products. It may take the form of pills or powders (regular
methamphetamine) or glassy rocks (crystal methamphetamine), and may be taken orally, smoked,
snorted, or injected (SAMHSA, 2016d). Chronic use of cocaine or methamphetamine can lead to
loss of appetite and significant weight loss (Riezzo, Fiore, De Carlo, et al., 2012). In addition to
being addicted to methamphetamine, chronic abusers may exhibit symptoms that can include
significant anxiety, confusion, insomnia, mood disturbances, and violent behavior. They also may
display a number of psychotic features, including paranoia, visual and auditory hallucinations, and
delusions (NIDA, 2013). Long-term cocaine use is linked with increased risk of stroke (Fonseca &
Ferro, 2013) and seizures. Studies also suggest that a wide range of cognitive functions such as
sustaining attention, impulse inhibition, memory, and performing motor tasks may be affected
(Spronk, van Wel, Ramaekers, & Verkes, 2013).

3 A note on sampling from the survey: “Estimated numbers of people refer to people aged 12 or older in the civilian,
noninstitutionalized population in the United States. The numbers do not sum to the total population of the United
States because the population for NSDUH does not include people aged 11 years old or younger, people with no
fixed household address (e.g., homeless or transient people not in shelters), active-duty military personnel, and
residents of institutional group quarters, such as correctional facilities, nursing homes, mental institutions, and longterm hospitals” (Center for Behavioral Health Statistics and Quality, 2015a). This may be an underestimate.
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M ATERNAL E FFECTS
Although some studies have documented a greater prevalence of health problems in pregnant
women who use certain substances, particularly stimulants, these health problems may also be
caused by other health factors that may be more prevalent in women who are more likely to use
such drugs, rather than the drugs themselves.
Rates of placental abruption (premature separation of the placenta from the inside wall of the
uterus) are higher in women who have used cocaine during their pregnancies (Rosenak, Diamant,
Yaffe, & Hornstein, 1990), as are the rates of placental hemorrhages (especially when cocaine is
taken with methamphetamine, another stimulant) (Oro & Dixon, 1987). Both events can be
dangerous for the mother, and may end in fetal loss (Ananth & Wilcox, 2001). Cocaine use also
leads to higher blood pressure, which is one of the biggest risks to maternal health during a
pregnancy and may affect the mother after pregnancy as well.
Mothers who used cocaine during their pregnancies may be at slightly higher risk for mood
disorders postpartum. One study found that maternal psychological distress postpartum was 20%
higher in women who used cocaine than in their non-using high-risk counterparts (Singer et al.,
2002). A smaller study credits the depressed mood of postpartum cocaine-using mothers to a lower
level of circulating oxytocin (Light et al., 2004).
Maternal and fetal effects of methamphetamine are like those of cocaine, as both are the same class
of drugs and affect the body in a similar way. It is not clear whether methamphetamines alone can
cause pregnancy complications, such as placental hemorrhages and raised blood pressure (Oro &
Dixon, 1987). Studies have found that up to 89% of women who use methamphetamine also use
other drugs concurrently – including legal drugs such as alcohol and tobacco (Della Grotta et al.,
2010; Good, Solt, Acuna, Rotmensch, & Kim, 2010) –– both of which have been shown to increase
a woman’s risk of experiencing pregnancy complications.
Amphetamine use can reduce breast milk supply (Anderson, 1991). The American College of
Obstetricians and Gynecologists (ACOG) recommends that women who are using amphetamines
do not breastfeed for two main reasons: the concentration of amphetamines are higher in breast
milk than in plasma, and street drugs often include unknown substances that may further harm both
the mother and child (ACOG, 2011).

F ETAL /N EONATAL E FFECTS
The fetal and neonatal effects of cocaine, as with many other illegal drugs, are difficult to
measure due to ethical considerations of researchers, self-reported data, and confounding effects
of other concurrent exposures, including other drugs a woman may take and aspects of her
environment. Moreover, the published research may reflect some bias because research that
found no adverse effects has been shown to be significantly less likely to be accepted for
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publication (Koren, Graham, Shear, & Einarson, 1989).
In the literature, cocaine use is most often associated with fetal growth decrements and has shown
dose-response outcomes (Behnke & Smith, 2013; Schempf, 2007). Cocaine use during the period of
pregnancy where the brain and nervous system are developing may result in permanent changes to
the brain and nervous system (Stanwood & Levitt, 2004). Studies have linked cocaine use to
underdevelopment in the parts of the brain that regulate attention and executive functioning (Frank,
Augustyn, Knight, Pell, & Zuckerman, 2001).
Methamphetamine use is associated with babies that are small for their gestational age (ACOG,
2011; Eriksson, Jonsson, Steneroth, & Zetterström, 2008; Smith et al., 2003). Methamphetamine
exposure in utero may result in smaller brain volume, which affects attention and memory. One
small study found that children exposed to methamphetamine in utero had smaller brain volumes in
the part of the brain responsible for sustained attention and verbal memory. The children also
scored lower on tests of attention, visual motor integration, verbal memory, and long-term spatial
memory (L. Chang et al., 2004).

L ONG - TERM E FFECTS

OF

C RACK C OCAINE : N OT W HAT W AS F EARED

Because of the “crack baby” myth of the late 1980s, more long-term data exist for gestational
cocaine exposure than many other drugs. Researchers have generally concluded that the fear of longlasting health and development implications for children born to mothers who use cocaine is unfounded.
Many studies of children whose mothers used cocaine during pregnancy involved women in poverty
or using public assistance. One of the first researchers to investigate the long-term effect of in-utero
cocaine exposure, Hallum Hurt, noted that “poverty is a more powerful influence on the outcome
of inner-city children than gestational exposure to cocaine” (Farah et al., 2006; FitzGerald, 2013).
A systematic review of 31 studies found women who used cocaine during pregnancy were
significantly more likely to experience preterm birth and to give birth to infants who had low
birthweight or were small for their gestational age. The researchers also found that infants born to a
mother who used cocaine had early gestational age at delivery (approximately 1.5 weeks earlier) and
reduced birthweight (approximately 1 pound lighter) (Gouin, Murphy, & Shah, 2011).
An earlier systematic review of 36 studies assessing the neonatal impact of maternal cocaine use
found little evidence of long-lasting negative impacts when controlling for other factors, including
maternal alcohol and tobacco use. The review found that neonatal and long-term effects of cocaine
were largely exaggerated. After controlling for confounders across studies, the most consistent
effects of cocaine were fetal growth decrements and below optimal neonatal state regulation and
motor performance (Frank et al., 2001). Differences in infant movement and temperature regulation
were only observed up to seven months of age.
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Another review of 31 studies found that compared to non-drug-exposed infants, cocaine-exposed
infants had higher rates of major malformations, low birthweight, prematurity, placental abruption,
premature rupture of membrane (PROM), and lower mean birthweight, length, and head
circumference (Addis, Moretti, Ahmed Syed, Einarson, & Koren, 2000). However, importantly,
most of the negative effects were not observed when cocaine-exposed infants were compared to
infants exposed to other illicit drugs. The researchers here concluded that only the risk of placental
abruption and premature rupture of membranes were statistically associated with cocaine use itself.
Hurt and others have published many studies on a cohort of low-SES children, approximately half
of whom were exposed to cocaine in utero, at different stages throughout their lives. Overall, the
children do not differ in their health, development, or academic achievement. Children at two-and-ahalf years old showed no differences in language development compared to their peers (Hurt,
Malmud, Betancourt, Brodsky, & Giannetta, 1997). At four years old, the case and control groups
did not differ in IQ scores (Hurt, Malmud, Betancourt, Braitman, Brodsky, & Giannetta, 1997). No
neurological differences were associated with gestational cocaine exposure at six years old (Hurt,
Giannetta, Brodsky, Malmud, & Pelham, 2001). Children had similar rates of successful grade
progression through grades 1-4 and similar GPAs, as well as similar rates of reading below grade
level and having below average standardized test scores (Hurt, Brodsky, Roth, Malmud, &
Giannetta, 2005). At 10 years old, the children showed subtle problems in attention and impulse
control that may be associated with maternal cocaine use in utero. Although the discrepancies were
relatively minor, the researchers noted that “exposed children [were] at higher risk of developing
significant behavioral problems as cognitive demands increase” (Savage, Brodsky, Malmud,
Giannetta, & Hurt, 2005). Compared to their non-exposed peers, adolescents exposed to cocaine in
utero showed no evidence of the exposure affecting inhibitory control, working memory, or
receptive language, but exposure was associated with slightly worse incidental face memory and
word memory (Betancourt et al., 2011). A different study of the same cohort of teenagers showed
no difference in pre-frontal cortex activation on functional magnetic resonance imaging (fMRI)
scans (Hurt et al., 2008).

O PIOIDS

AND

O PIATES

Opioids are a class of drug typically used for pain relief whose effect on the body is similar to that of
opium, a narcotic substance derived from a specific poppy plant. Opiates are drugs derived from
opium. At one time “opioids” referred only to synthetic opiates (drugs created to emulate opium but
chemically different). Now the term “opioid” is used for the entire family of opiates (including natural,
synthetic, and semi-synthetic), which bind to opioid receptors in the brain and body (NIDA, 2016).
The following prescription pain relievers are opioids:


Codeine and hydrocodone (brand name Vicodin®)



Fentanyl (brand names Actiq®, Duragesic®, Sublimaze®)
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Morphine (brand names Kadian®, Avinza®)



Oxycodone (brand names OxyContin®, Percocet®)



Tramadol (brand names ConZip®, Ryzolt®, Ultram®)

Heroin is a drug made from the opioid morphine. In some countries it is available legally, by
prescription from a healthcare provider, but not in the United States. Heroin can be injected,
smoked, swallowed, or sniffed. All routes of administration deliver the drug to the brain very rapidly,
which contributes to its health risks and to its high risk for addiction (NIDA, 2014b). When it enters
the liver, heroin is converted back into morphine, which binds to molecules on cells known as
opioid receptors. These receptors are located in many areas of the brain (and elsewhere in the body),
especially those involved in the perception of pain and in reward. Opioid receptors are also located
in the brain stem, which controls automatic processes critical for life, such as blood pressure,
arousal, and respiration.
Heroin overdoses, which often result from using heroin in combination with another drug, involve a
suppression of breathing. This can reduce the amount of oxygen that reaches the brain, a condition
called hypoxia. Hypoxia can have short- and long-term psychological and neurological effects,
including coma and permanent brain damage.
According to the Substance Abuse and Mental Health Services Administration (SAMHSA), opioids
also have “great potential for misuse” (SAMHSA, 2016b). In 2014, 1.9 million people had a
substance use disorder involving prescription pain relievers and 586,000 had a substance use
disorder involving heroin (Center for Behavioral Health Statistics and Quality, 2015a). The
prescription-to-heroin path is described as resulting from easier heroin availability when individuals
are unable to obtain their preferred prescription opioid (Compton, Jones, & Baldwin, 2016).
Researchers are investigating the long-term effects of repeated opioid use on the brain. One result is
tolerance, in which more of the drug is needed to achieve the same intensity of effect. Another result
is dependence, characterized by the need to continue use of the drug to avoid withdrawal symptoms.
Studies have shown heroin use to cause some deterioration of the brain’s white matter, which may
affect decision-making abilities, the ability to regulate behavior, and responses to stressful situations
(Darke, 2013; NIDA, 2014b).
Heroin use is associated with fatal overdose, miscarriage, and infectious diseases such as hepatitis
and HIV (NIDA, 2014c). Chronic users may develop collapsed veins, infection of the heart lining
and valves, abscesses, constipation and gastrointestinal cramping, and liver or kidney disease.
Pulmonary complications, including various types of pneumonia, may result from the poor health of
the user as well as from heroin’s effects on breathing. In addition to the effects of the drug itself,
street heroin often contains toxic contaminants or additives that can clog blood vessels leading to the
lungs, liver, kidneys, or brain, causing temporary or permanent damage to vital organs (NIDA, 2014b).
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Rates of heroin use and heroin overdose have been increasing in the U.S. In 2014, 435,000 people
over age 12 in the U.S. used heroin (Center for Behavioral Health Statistics and Quality, 2015a).
Prescription opioids are the leading cause of fatal drug overdoses, with nearly 30,000 deaths in 2014
(accounting for three-fifths of all fatal drug overdoses) (Centers for Disease Control and Prevention
[CDC], 2015a). Multiple first responder agencies have encouraged or required personnel to carry
Naloxone (brand name Narcan®) to treat opioid overdoses in emergency situations.

M ATERNAL E FFECTS
Opioid use in pregnancy includes the appropriate use of opioid medication under a prescriber’s care,
the misuse of opioid prescription medication, and the use of heroin. The social circumstances
associated with illicit drug use put a pregnant woman, particularly a low-income pregnant woman
without adequate financial resources to obtain drugs safely, at risk of engaging in activities such as
prostitution, theft, and violence. Such activities often expose women to sexually transmitted
infections and violence. Punitive responses to opioid use put pregnant women at additional risk for
harm in the form of legal consequences, including loss of child custody, criminal proceedings, or
incarceration (ACOG & American Society of Addiction Medicine [ASAM], 2012).
Pregnant women who misuse substances are also at high risk for malnourishment (Finnegan, 2016),
often lacking adequate obstetric care (NIDA, 2014b) and remaining in a violent environment
(Jansson et al., 1996). Among pregnant women who continue intravenous heroin consumption, the
risks of medical complications such as infectious diseases, endocarditis, abscesses, and sexually
transmitted infections are increased (Winklbaur et al., 2008).

F ETAL /N EONATAL E FFECTS
Prenatal opioid exposure may be associated with increased risk of low birth-weight, intrauterine
growth restriction, neonatal withdrawal, and negative newborn neurobehavioral outcomes (Behnke
& Smith, 2013). Infants prenatally exposed to opioids, including methadone or buprenorphine
within the context of addiction treatment, may experience neonatal abstinence syndrome (NAS)
(Kennedy-Hendricks, McGinty, & Barry, 2016). Multiple studies have found an association between
first-trimester use of codeine and congenital heart defects. Infants born with NAS also are more
likely to exhibit intrauterine growth restriction, lower birth weight, and smaller head circumference,
and to be smaller for gestational age (Wendell, 2013). (See Box 2 for more details.)
Compared to the relative effects of alcohol, cocaine, or benzodiazepine abuse during pregnancy,
opioids do not disturb the development of the fetus or harm living cells (Winklbaur et al., 2008).
These findings support treatment protocols that avoid detoxification. In their 2014 study, Whiteman
and colleagues found maternal opioid use during pregnancy was associated with increased odds of
threatened preterm labor, early onset delivery, and stillbirth (Whiteman et al., 2014).
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B OX 2. N EONATAL A BSTINENCE S YNDROME
Neonatal Abstinence Syndrome (NAS) occurs when a child born to a substance-using mother
develops a passive dependency to the substance, and expresses symptoms once the supply of
the drug is cut off after birth (Finnegan, 2016).
NAS is usually apparent within the first 24-72 hours after birth. These symptoms are temporary
and generally last a few weeks.
NAS symptoms fall into four clinical categories: central nervous system signs (including
irritability, crying, tremors, and seizures), gastrointestinal signs (including vomiting and
diarrhea), respiratory signs (including abnormal or rapid breathing), and autonomic nervous
system signs (including sneezing, tearing, yawning, and sweating) (Finnegan, 2016).
Several factors affect whether an infant will experience NAS, including separation from the
mother and genetics. NAS can occur in the infants of women who are currently undergoing
medication-assisted treatment and are no longer using drugs illicitly. Prescription opioid
dependency medication, such as methadone, also can cause the infant to experience NAS
(Finnegan, 2016).

A LCOHOL
Although alcohol is legal for those 21 or over, it can still be a dangerous substance with excessive
use. In 2014, approximately one-fourth of people 12 or older were binge alcohol users (defined as
having five or more drinks in one sitting in the last month) (Center for Behavioral Health Statistics
and Quality, 2015a), and approximately 6% of people were heavy alcohol users (defined as having
five or more binge days in the last month). More than one-third of young adults (ages 18-25) in 2014
were binge alcohol users, and approximately 1 in 10 were heavy alcohol users (Center for Behavioral
Health Statistics and Quality, 2015a). Binge drinking is linked to worse health effects than moderate
drinking, and nearly one-fourth of people aged 12 or older have had a binge drinking episode within
the last month of being surveyed (Center for Behavioral Health Statistics and Quality, 2015a).

M ATERNAL E FFECTS
Research shows that women start to have alcohol-related problems at lower drinking levels than
men do (McGarry & Cyr, 2005). Alcohol interferes with the brain’s communication pathways, and
can affect the way the brain looks and works. These disruptions can change mood and behavior, and
make it harder to think clearly and move with coordination.
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Data from prenatal clinics and postnatal studies suggest that 20-30% of women do drink at some
time during pregnancy (Pruett, Waterman, & Caughey, 2013). In 2016, the CDC released a report on
women’s contraceptive use and drinking habits, which was used to calculate how many women were
“at risk of exposing their developing baby to alcohol because they are drinking, sexually active, and
not using birth control to prevent pregnancy” (CDC, 2016). This report was generally interpreted
through the media as a recommendation that women at risk for pregnancy who are not using birth
control consume no alcohol. A director quoted in the report says, “[women] may not be aware that
drinking any alcohol at any stage of pregnancy can cause a range of disabilities for their child” (CDC,
2016). Many criticized the advice as being overly broad, impractical, or suggesting that women’s
reproductive roles take precedence above other aspects of their lives. Some noted that the absence
of an established safe level of drinking does not mean that no such level exists, but that research to
date has not identified it.

F ETAL /N EONATAL E FFECTS
Prenatal alcohol exposure is a leading preventable cause of birth defects and neurodevelopmental
abnormalities in the United States. Alcohol has teratogenic potential, meaning that it can disturb
fetal development, especially affecting the fetal central nervous system with potentially severe lifelong consequences (Winklbaur et al., 2008). This disruption can cause a range of developmental,
cognitive, and behavioral problems, which can appear at any time during childhood and last a
lifetime. The most profound effects of prenatal alcohol exposure are brain damage (including
anatomic and structural changes and decrease in size) and the resulting impairments in behavioral
and cognitive functioning (Pruett et al., 2013).
Growth restriction is one of the hallmarks of prenatal alcohol exposure and must be present to
establish a diagnosis of Fetal Alcohol Syndrome. It is important to note that most infants born with
alcohol exposure do not have FAS. However, even a moderate amount of alcohol use during
pregnancy is associated with a decrease in size at birth (Behnke & Smith, 2013). Fetal alcohol
syndrome is an umbrella term describing the range of effects that can occur in an individual
prenatally exposed to alcohol. The main features of Fetal Alcohol Syndrome are microcephaly (with
severe brain effects); prenatal and growth restriction; and facial anomalies. The overall effects of
fetal alcohol exposure are designated as Fetal Alcohol Spectrum Disorder (FASD), with FAS as the
“tip of the iceberg” (Kowalsky & Verhoef, 1999). Prenatal alcohol exposure is linked with significant
attention problems in children as well as adaptive behavior problems spanning early childhood to
adulthood (Shankaran et al., 2007), including disrupted school experiences, delinquent and criminal
behavior, and substance abuse.
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B OX 3. F ETAL A LCOHOL S PECTRUM D ISORDERS
Fetal alcohol spectrum disorders (FASDs) are a group of conditions that can occur in a
person whose mother drank alcohol during pregnancy (CDC, 2015b). These effects can
include physical problems and problems with behavior and learning. Often, a person with an
FASD has a mix of these problems. Different terms are used to describe FASDs, depending
on the type of symptoms.
The term fetal alcohol effects (FAE) was previously used to describe intellectual disabilities
and problems with behavior and learning in a person whose mother drank alcohol during
pregnancy. In 1996, the Institute of Medicine (IOM) replaced FAE with the terms alcoholrelated neurodevelopmental disorder (ARND) and alcohol-related birth defects (ARBD)
(Stratton, Howe, & Battaglia, 1996).


Fetal Alcohol Syndrome (FAS): FAS represents the most involved end of the FASD
spectrum. Fetal death is the most extreme outcome from drinking alcohol during
pregnancy. People with FAS might have abnormal facial features, growth problems, and
central nervous system (CNS) problems. People with FAS can have problems with
learning, memory, attention span, communication, vision, or hearing. They might have a
mix of these problems. People with FAS often face difficulties in school and trouble
getting along with others.



Alcohol-Related Neurodevelopmental Disorder (ARND): People with ARND might
have intellectual disabilities and problems with behavior and learning. They might do
poorly in school and have difficulties with math, memory, attention, judgment, and poor
impulse control.



Alcohol-Related Birth Defects (ARBD): People with ARBD might have problems with
the heart, kidneys, or bones or with hearing. They might have a mix of these.

M ARIJUANA (C ANNABIS )
Marijuana (including hashish, or hash, a compressed or purified form of the cannabis plant) was the
most commonly used illicit drug in 2014, and it is typically smoked or ingested. In one study, over
80% of all people who used at least one type of drug for non-medical purposes in the last month
used marijuana (Center for Behavioral Health Statistics and Quality, 2015a). The usage rate in
individuals 12 and over has increased to 48.4%, up from 5.8-6.2% from 2002-2007 (Center for
Behavioral Health Statistics and Quality, 2015a).
The primary active compound in marijuana is trans-delta-9-tetrahydrocannabinol (D9-THC, or
simply THC). THC attaches to cannabinoid receptors located throughout the body. The
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cannabinoid receptor most associated with the feeling of being “high” is primarily located in the
brain. The levels of active compounds are measured in state-regulated marijuana dispensaries, but
are typically unknown in marijuana bought on the street.
Twenty-six states and the District of Columbia currently have laws legalizing marijuana in some
form. Three other states will soon join them after recently passing measures permitting use of
medical marijuana (Governing.com, 2016).

M ATERNAL E FFECTS
Women who use marijuana during pregnancy tend to be younger and of lower parity, and to have
higher rates of cigarette smoking, alcohol, caffeine, and illicit drug use during pregnancy than
mothers who do not use marijuana (Fergusson, Horwood, & Northstone, 2002). Cannabinoids may
have a relaxant effect on a woman’s myometrium (a layer of muscle in the uterus) while she is
pregnant, although it has not been found to affect rates of premature labor (Dennedy et al., 2004).
Women have reported cannabis as being effective against morning sickness during pregnancy
(Westfall, Janssen, Lucas, & Capler, 2006).

F ETAL /N EONATAL E FFECTS
Conner et al. utilized a meta-analysis of 31 studies to provide insight into the fetal and neonatal
effects of marijuana. Although the unadjusted data showed a correlation between marijuana use and
low birthweight, there was no statistically significant increased risk of low birthweight when the
researchers controlled for use of tobacco and other confounders (Conner et al. 2016). An earlier
analysis of studies of infant outcomes and maternal marijuana use was unable to conclude that
maternal marijuana use caused lower birthweight, morphologic abnormalities, or abnormal
neurobehavioral outcomes (Day & Richardson, 1991). This analysis found mixed evidence for all
three measures, but none was consistent enough to establish a causal relation. Another study of
approximately 12,000 pregnant women, 600 of them marijuana users, found that marijuana use was
not associated with increased risk of perinatal mortality or morbidity. The researchers found an
association between marijuana use during pregnancy and low infant birthweight, but the association
was not statistically significant after controlling for other confounding factors (Fergusson et al., 2002).
However, frequent and regular use of cannabis throughout pregnancy may be associated with small
but statistically detectable decrements in birthweight. Several studies were complicated by women’s
use of other drugs when the researchers were trying to find a relationship for marijuana alone. There
is no proven causal link for any effect of prenatal cannabis exposure.
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B OX 4. P REGNANT

WOMEN IN RESEARCH

Pregnant women are typically not included in the prescription drug research process, due to
ethical concerns. The Code of Federal Regulations includes ten requirements for involving
pregnant women as research participants, including conditions of reducing risk to the mother and
child, proving direct benefit to the mother, performing scientifically appropriate preclinical studies
(e.g., studies on pregnant animals or nonpregnant women), and having researchers take no part in
the decision of whether or not to terminate the pregnancy (Research Involving Pregnant Women
or Fetuses, 2009). However, the dearth of studies involving pregnant women is problematic for
pregnant or breastfeeding women and their babies, particularly for studies of new drugs under
development where there is limited clinical experience with this group to give indications of
safety. Some, including Lyerly et al., identify the four main reasons why an ethical obligation exists
to include pregnant women in clinical research: women’s need for effective treatment during
pregnancy, fetal safety, doctors’ unease in prescribing needed medications, and broader issues of
justice and access to benefits of research participation (Lyerly, Little, & Faden, 2008).
The U.S. Food & Drug Administration (FDA) offers a master list of Pregnancy Exposure
Registries used to track information about prescription drugs and vaccines that may affect
pregnancies. A pregnant woman who is currently taking prescription drug(s) or currently has a
medical condition may sign up for the registry, and will intermittently be asked about her status
during the pregnancy and her and her baby’s status postpartum. Studies using registry data are
particularly useful for medical conditions that require ongoing or episodic treatment, such as
asthma, epilepsy, or hypertension (FDA CDER 2004).
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T REATMENT

I NTERVENTIONS

AND

C OMPONENTS

Many evidence-based methods of SUD treatment exist and are offered in SUD treatment programs.
The most effective treatments will be culturally appropriate, women-centered, and meet women’s
complex needs. These include treating other physical and mental health conditions and providing
support to reduce common barriers to treatment, such as challenges with childcare and
transportation. Research has shown that harm reduction strategies, aimed at reducing the negative
consequences of drug use, can also be also a valuable component of treatment for people with
substance use disorders. Box 7, from SAMHSA’s 2009 Treatment Improvement Protocol, shows
recommended services to include in treatment options for women. Such comprehensive services for
pregnant women with SUD have been recommended for decades (Finnegan, Hagan, and
Kaltenbach, 1991). However, it can be difficult for women, and pregnant women in particular, to
find and access treatment programs designed to meet their needs. These difficulties can be
compounded for women who are un- or under-insured.
Pharmacologic treatment options are rare, except for opioid use disorders. No drugs are currently
approved by FDA to treat cocaine, methamphetamine, or cannabis addiction. The drugs that are
approved to treat alcohol addiction – Acamprosate, Disulfiram, and Naltrexone – have not been
tested in samples of pregnant women, and are not widely recommended, as the benefits have not
been clearly established for all. Pregnant women have not been participants in the large-scale studies
of buprenorphine and methadone, but both drugs have been tested in pregnant women and found
to have low risks. However, these drugs may cause Neonatal Abstinence Syndrome in the infant
(referred to as “neonatal opioid withdrawal syndrome” in the FDA label).

B OX 5. I NTERVENTION D EFINITIONS
The following types of interventions may be used together or separately as parts of comprehensive
treatment approaches. This is not an exhaustive list of treatment options.
Cognitive Behavioral Therapy (CBT) – CBT focuses on helping clients identify and avoid situations in
which they are likely to use substances and to “cope more effectively with the variety of situations,
feelings, and behaviors related to their substance abuse” (SAMHSA, 1999).
Community Reinforcement Approach (CRA) – CRA works to reduce the reinforcement clients
receive from substance use and increase reinforcement from alternative activities that are incompatible
with substance use. Alternatives can include vocational, family, social, and recreational activities, and
programs may make access to such activities contingent on remaining drug-free (SAMHSA, 1999).
Contingency Management – Based on analysis of the situations surrounding substance use, contingency
management associates evidence of substance use with negative consequences and abstinence-promoting
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behaviors with positive reinforcers. For instance, some programs reward participants with vouchers that
have monetary value when they submit drug-free urine samples (SAMHSA, 1999).
Medication-Assisted Therapy (MAT) – The term “MAT” typically refers to using methadone or
buprenorphine as part of treatment for opioid use disorder; this is the standard of care for opioid use
disorder in pregnancy. Medication can also be part of treatment for other SUDs, although research
involving pregnant women is insufficient on medications other than methadone and buprenorphine.
Motivational Interviewing – Often used in brief interventions, motivational interviewing involves using
a gentle, empathic style to “constructively and compassionately explore ambivalence about change and
motivation for recovery” (SAMHSA, 2009).
Screening, Brief Intervention, and Referral to Treatment (SBIRT) – Healthcare providers screen
patients for substance use disorders. For those who screen positive, the same providers deliver a brief
intervention – such as counseling or motivation interviewing – and provide a referral for additional
treatment (SAMHSA, 2009). Brief interventions “aim to investigate a potential problem and motivate an
individual to begin to do something about [her] substance abuse” (SAMHSA, 1999). However, research
calls into question the efficacy of SBIRT (e.g., Glass et al., 2015; Saitz, 2015), and routine screening of
pregnant women for substance use risks increasing child protective services (CPS) referrals without
achieving a meaningful increase in the number of women who receive effective SUD treatment (Roberts
& Nuru-Jeter, 2012).
12-Step Programs and Other Support Groups – Programs such as Alcoholics Anonymous (AA) are
peer-facilitated groups that offer support for establishing abstinence, developing recovery skills, and
maintaining recovery, although there is limited evidence of the effectiveness for women. AA was
established by, and primarily for, men, and the model’s limited focus on cultural and social issues relevant
to women’s substance use may serve as a barrier for some women. Women-only support groups and selfhelp programs, such as the Women for Sobriety program for alcohol-dependent women, are alternatives
to AA’s 12-step model (SAMHSA, 2009).

S CREENING , B RIEF I NTERVENTION ,

AND

R EFERRAL

TO

T REATMENT (SBIRT)

SBIRT is a recommended approach for providers to use with pregnant women (Center for
Substance Abuse Treatment, 2009; Wisner, Sit, et al., 2017), but evidence to support its use in
pregnant women and other populations is lacking. For instance, in 2013 the U.S. Preventive Services
Task Force (USPSTF) “found adequate evidence that brief behavioral counseling interventions are
effective in reducing heavy drinking episodes in adults engaging in risky or hazardous drinking” but
reported that evidence in pregnant women was more limited and that the evidence was insufficient
to make a recommendation on brief interventions for adolescents (Moyer, 2013). However, a
systematic review and meta-analysis of brief alcohol interventions in medical settings found a lack of
evidence that they increase the use of alcohol-related services (Glass et al., 2015). Saitz warns that
the evidence of brief alcohol interventions on clinically important outcomes is limited, and that
SBIRT may have limited effectiveness in patients with the most unhealthy use of alcohol and those
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who are ambivalent about change (Saitz, 2015). The USPSTF is in the process of updating its
recommendations on screening and behavioral counseling interventions for unhealthy alcohol use in
pregnant women (U.S. Preventive Services Task Force, 2016).
ACOG stresses the importance of applying routine screening equally to all people using validated
questionnaires or conversations with patients (ACOG, 2015). Brief interventions can consist of a
provider advising a patient to stop drug use while pregnant, or involve psychoeducational
counseling. Referrals to inpatient or outpatient care should be based on the severity of the condition
and patient needs (Wisner et al., 2017) – e.g., women who meet the criteria for SUD may benefit
from referral to a comprehensive treatment program. Directly scheduling an appointment for a
woman to see a specific treatment provider (direct linkage) can double the chances of the woman
seeing the provider in question (Haug, Duffy, & McCaul, 2014; Howell & Chasnoff, 1999).
Some researchers and advocates caution that it can be harmful to use SBIRT routinely with pregnant
women in the absence of evidence of its effectiveness for this population. If SBIRT is not leading to
women receiving effective treatment, then the screening essentially functions as surveillance for
reporting women to child protective services rather than as a path to better health (Roberts & NuruJeter, 2012). Screening may also result in women who disclose substance use being forcibly detained
in treatment facilities (Eckholm, 2013).

D ETOXIFICATION
Detoxification from alcohol or addictive drugs has typically involves three to five days in an
inpatient setting, with medical treatment for symptoms of withdrawal (Center for Substance Abuse
Treatment, 2009). The setting and duration of detoxification can vary based on the substance in
question and the expected severity of withdrawal. Pregnant patients who are undergoing detoxification
should do so slowly and in consultation with an obstetrician. An expert panel convened by SAMHSA
suggests “that for alcohol, sedative-hypnotic, and opioid withdrawal syndromes, hospitalization (or
some form of 24-hour medical care) is often the preferred setting for detoxification” (Center for
Substance Abuse Treatment, 2006). However, not all communities offer detoxification services, and
those available may not treat pregnant women because they lack the necessary obstetrical support
(Center for Substance Abuse Treatment, 2009). As discussed in “Opioids and Opiates” section
below, detoxification is not advised for pregnant women with opioid dependence.

H ARM R EDUCTION
Harm reduction approaches focus on reducing drug-related harm without requiring complete
cessation of substance use. The Society of Obstetricians and Gynecologists of Canada practice
guidelines state, “Perinatal healthcare providers can make a significant impact on improving
pregnancy outcomes by providing non-judgmental supportive care within a harm reduction model
to address substance use issues and social determinants of health” (Wong et al., 2011). Needle
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exchanges are perhaps the best-known example of harm reduction in the public health discipline,
allowing injection drug users to reduce their risk of acquiring HIV and other diseases transmitted
with shared needles. For pregnant women who use substances, harm reduction could include
reducing the amount of substance used or the frequency of use. Treatment programs can be
developed using harm reduction principles, and clients can receive harm reduction therapy, a form
of psychotherapy that focuses on setting and modifying goals that involve reducing harm. Clients
may aim for or achieve abstinence but are not required to do so under this approach. Rothschild
writes of harm reduction therapy, “No longer is the focus solely and absolutely on the substance
misuse. The therapy, like any other, involves a whole, complex person who is facing challenges in
life, one of which may be substance misuse” (Rothschild, 2010).
Studies have addressed a few different harm reduction approaches to caring for pregnant women
who use substances. A study at Kaiser Permanente Northern California (KPNC) investigated
outcomes among pregnant women who used alcohol in three different conditions. One intervention
group received KPNC’s Early Start services (involving integrated substance abuse treatment and
prenatal care), and the other received Early Start services plus a drink size assessment and
intervention that encouraged women to reduce their drinking if they could not abstain entirely.
Researchers found no significant differences in birth outcomes between the Early Start group and
the Early Start Plus group, which received the harm reduction message (Armstrong et al., 2009). A
2015 review concluded, “Comprehensive, integrated multidisciplinary services for pregnant women
with substance use disorder aimed at harm reduction are showing positive results,” and encourages
additional research (Kramlich & Kronk, 2015).
T REATMENT P ROGRAM C OMPONENTS
Treatment programs vary in structure and in the interventions they use. Some components may be
especially important in allowing women to access and complete the program.
In a systematic review of randomized controlled trials of psychosocial interventions for pregnant
women enrolled in treatment programs for illicit drug use, Terplan and colleagues found 14 studies
that compared psychosocial interventions to controls. Nine studies involved interventions using
contingency management, which includes positive reinforcement (such as vouchers) to reward
desired behaviors, and five studies addressed motivational interviewing interventions, in which
client-centered counseling helps participants improve their readiness to change. Overall, the authors
of this review did not find differences in mothers’ retention or treatment when comparing
intervention and control groups, but they did find that neonates born to contingency management
participants spent fewer days in the hospital. However, the authors caution that the included trials
rarely captured maternal and infant outcomes of interest, and that the overall quality of evidence was
only low to moderate. Terplan and colleagues stress the need to develop a better evidence base on
psychosocial treatments for pregnant women with illicit substance use disorders (Terplan,
Ramanadhan, Locke, Longinaker, & Lui, 2015).
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While the large majority of SUD treatment facilities may accept women as clients, a minority offer
programs specifically tailored to women (Terplan, McNamara, & Chisolm, 2012). Research shows
that women are more likely to enroll and remain in treatment when they use women-centered
programs, so the availability of such programs influences the likelihood of treatment success (Haug
et al., 2014). Allowing women to bring their children with them to residential treatment programs
can remove a barrier to treatment and have a positive effect on retention and recovery (Ashley,
Marsden, & Brady, 2003; Center for Substance Abuse Treatment, 2009; Hughes et al., 1995; Stevens,
Arbiter, & Glider, 1989; Szuster, Rich, Chung, & Bisconer, 1996; Wobie, Eyler, Conlon, Clarke, &
Behnke, 1997). Availability of childcare and other services designed to reduce common treatment
barriers are also important for women’s ability to enter and continue treatment (American Society of
Addiction Medicine [ASAM], 2011; Brown, Vartivarian, & Alderks, 2011; Heslin, Gable, &
Dobalian, 2015; Lester, Andreozzi, & Appiah, 2004; SAMHSA, 2009; Terplan, McNamara, &
Chisolm, 2012). Comprehensive case management for both medical and social needs can improve
attendance and outcomes (Haug et al., 2014; SAMHSA, 2009).
Generally, women may have childcare or work responsibilities that make entry into residential
programs impracticable. Findings from an exploratory study using national Treatment Episode Data
Set (TEDS) data from 2006-2010 suggest that for pregnant women with children, outpatient
programs may be especially effective because participants have better access to childcare and the
ability to remain at home with their children. Sahker and colleagues examined the proportion of
pregnant women who successfully completed treatment in eight different service settings (detox—
hospital inpatient, detox—freestanding residential, detox—ambulatory, rehab—hospital residential,
rehab—short-term residential, rehab—long-term residential, intensive outpatient, and non-intensive
outpatient) to the proportion of non-pregnant women with successful completion. For seven of the
eight settings, a larger percentage of non-pregnant women successfully completed the treatment
(though not all differences were statistically significant). The only setting for which a greater
proportion of pregnant women completed treatment was the non-intensive outpatient setting (45%
of pregnant women vs. 41% of non-pregnant women) (Sahker, McCabe, & Arndt, 2016). Even
though outpatient treatment may be more feasible for pregnant women, and potentially more
effective than it is for non-pregnant women, some insurers may cover only residential treatments or
otherwise exclude outpatient treatment programs (American Congress of Obstetricians and
Gynecologists, 2015).
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B OX 6. FDA D RUG L ABELING

FOR

M EDICATION U SE D URING P REGNANCY

The current FDA labeling for medication use during pregnancy and breastfeeding utilizes three
subsections to provide information for several relevant populations. The subsections are
“Pregnancy,” “Lactation,” and “Females and Males of Reproductive Potential.” The FDA news
release describing the labeling explains each category further:
The Pregnancy subsection will provide information relevant to the use of the drug in pregnant women,
such as dosing and potential risks to the developing fetus, and will require information about whether there
is a registry that collects and maintains data on how pregnant women are affected when they use the drug or
biological product. Information in drug labeling about the existence of any pregnancy registries has been
previously recommended but not required until now.
The Lactation subsection will provide information about using the drug while breastfeeding, such as the
amount of drug in breast milk and potential effects on the breastfed child.
The Females and Males of Reproductive Potential subsection will include information about
pregnancy testing, contraception and about infertility as it relates to the drug. This information has been
included in labeling, but there was no consistent placement for it until now.
The “Pregnancy” and “Lactation” subsections will also include three subheadings: “risk summary,”
“clinical considerations” and “data.” These subheadings will provide more detailed information regarding,
for example, human and animal data on the use of the drug, and specific adverse reactions of concern for
pregnant or breastfeeding women. (FDA, 2014)
Under the previous (and longstanding) labeling rules, drugs were placed in one of five categories
— A, B, C, D, or X — depending on research findings (or lack thereof). An “A” designation
meant that human studies did not find adverse effects in pregnant women or their babies, while
and “X” designation meant that studies in humans or animals found a risk of problems to the
baby and/or that there were no situations in which the potential benefits of the drug would
outweigh the risks. The B, C, and D categories were for drugs with varying levels of evidence.
Most drugs are still categorized as “C,” often due only to lack of robust evidence on the
effect of the drug on pregnancy, due to ethical considerations for including pregnant
women in studies such as randomized controlled trials. Sandra Kweder, M.D, deputy
director of the Office of New Drugs in FDA’s Center for Drug Evaluation and Research,
described the letter system as “overly simplistic,” and noted that many people understood the
rankings as a grading system that over-simplified the product risk (FDA, 2014). The current
labeling encourages doctors and pregnant or breastfeeding women to have better conversations
about specific risks on a case-by-case basis, and to acknowledge where any gaps in the research
may exist.
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A CCESSIBILITY

OF

T REATMENT

In 2014, the most recent year for which SAMHSA has published findings from its National Survey
of Substance Abuse Treatment Services (N-SSATS), only 44% (6,212 of 14,152) of treatment
facilities offered programs specifically for adult women, and only 20% (2,795) offered programs for
pregnant or postpartum women. The percentage of facilities with programs for pregnant/
postpartum women varied from fewer than 10% of facilities in Hawaii (14 out of 177) and Montana
(6 out of 69) to more than 30% in Delaware (12 out of 39), South Carolina (35 out of 110), and
Vermont (16 out of 47) (SAMHSA, 2013).
The facilities that offer programs for pregnant women may or may not be the same ones offering
the many other services that help meet women’s needs. Out of all facilities, only 25% offered
residential treatment in 2014. Sixty percent of facilities accepted Medicaid payments, and 47%
offered treatment at no charge for clients who cannot pay. In 2014, services were available in
American Sign Language at 29% of facilities, and in languages other than English at 44%. Just 3%
offered residential beds for clients’ children (SAMHSA, 2013).
In a study of facilities that offered women-centered drug treatment (not specific to pregnant
women) between 2002 and 2009, Terplan and colleagues (2015) found that those with programs for
women were more likely than those not offering women-centered services to also offer childcare,
housing assistance, domestic violence counseling, transportation assistance, and residential beds for
children. Even so, fewer than half offered these services, which can reduce women’s barriers to
treatment (Terplan, Longinaker, & Appel, 2015).
Terplan and colleagues also found that facilities were less likely to provide women-centered services
if they were located in nonmetropolitan areas or in the Midwest or South. Medicaid funded facilities
were more likely to offer programs for women, while those that reported accepting Medicare and
military insurance were less likely to do so (Terplan, Longinaker, et al., 2015). In an analysis of 2012
N-SSATS data, Heslin and colleagues (2015) examined the ownership types of treatment facilities,
and found that local, county, or community facilities were most likely to offer programs exclusively
for women, while Veterans Administration (VA) facilities were the least likely. They also examined
key services that can facilitate women’s access to treatment: childcare; domestic violence services;
trauma counseling; assistance obtaining social services such as the Special Supplemental Nutrition
Assistance Program for Women, Infants, and Children (WIC); employment assistance; housing
assistance; transportation; and residential beds for children. In this analysis, they found VA facilities
and local/county/community facilities offered the same mean number of key service (3.57), with
only tribal-owned facilities offering more (3.72), and private for-profit facilities offering substantially
fewer (2.70). They also found facilities offering more programs to special populations were more
likely to have programs or groups exclusively for women and to provide key services, and that
facilities in urban areas were more likely to offer an array of key services (Heslin et al., 2015).
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Brown and colleagues (2011) analyzed 2008 N-SSATS data to explore the availability of childcare at
outpatient treatment facilities that accepted women. Out of 7,447 facilities, only 484 (7%), offered
childcare. Three-quarters of the 484 facilities accepted Medicaid, and 76% offered free treatment;
69% were non-profit, and 20% were operated by a government agency. More than half of the
childcare-providing facilities were located in metropolitan areas. Facilities that accepted only women
were far more likely (three times higher odds) to provide childcare than were those accepting both
women and men, but even so, only approximately one-quarter of these women-only facilities made
childcare available to clients (Brown et al., 2011).

B OX 7: S ERVICES N EEDED IN W OMEN ’ S S UBSTANCE A BUSE T REATMENT
Source: Center for Substance Abuse Treatment (SAMHSA), Substance Abuse Treatment: Addressing the
Specific Needs of Women, 2009
The following services are recommended by the [SAMHSA Center for Substance Abuse and Treatment]
consensus panel and reinforced by some State standards (CSAT 2007), and these services may be warranted
across the continuum of care beginning with early intervention and extending to continuing care services.
More than ever, services need to be tailored to women’s needs and to address the specific hardships they
often encounter in engaging treatment services. Promising practices designed to treat women with substance
use disorders include comprehensive and integrated clinical and community services that are ideally delivered
at a one-stop location.
Note: This list does not incorporate the customary services that are provided in standard substance abuse
treatment, but rather services that are more reflective of women’s needs.
Medical Services
Gynecological care
Family planning
Prenatal care
Pediatric care
HIV/AIDS services
Treatment for infectious diseases, including viral hepatitis
Nicotine cessation treatment services
Health Promotion
Nutritional counseling
Educational services about reproductive health
Wellness programs
Education on sleep and dental hygiene
Education about STDs and other infectious diseases; e.g., viral hepatitis and HIV/AIDS
Preventive healthcare education
Psychoeducation
Sexuality education
Assertiveness skills training
Education on the effects of alcohol and other drugs on prenatal and child development
Prenatal education
Gender-Specific Needs
Women-only programming; e.g., is the patient likely to benefit more from a same-sex versus
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mix-gender program due to trauma history, pattern of withdrawal among men, other issues.
Lesbian services
Cultural and Language Needs
Culturally appropriate programming
Availability of interpreter services or treatment services in native language
Life Skills
Money management and budgeting
Stress reduction and coping skills training
Family and Child-Related Services
Childcare services, including homework assistance in conjunction with outpatient services
Children’s programming, including nurseries and preschool programs
Family treatment services including psychoeducation surrounding addiction and its
impact on family functioning
Couples counseling and relationship enrichment recovery groups
Parent/child services, including developmentally age-appropriate programs for children and education for
mothers about child safety; parenting education; nutrition; children’s substance abuse prevention curriculum;
and children’s mental health needs, including recreational activities, school, and other related activities
Comprehensive Case Management
Linkages to welfare system, employment opportunities, and housing
Integration of stipulations from child welfare, TANF, probation and parole, and other systems
Intensive case management, including case management for children
Transportation services
Domestic violence services, including referral to safe houses
Legal services
Assistance in establishing financial arrangements or accessing funding for treatment services
Assistance in obtaining a GED or further education, career counseling, and vocational training, including job
readiness training to prepare women to leave the program and support themselves and their families
Assistance in locating appropriate housing in preparation for discharge, including referral to transitional living
or supervised housing
Mental Health Services
Trauma-informed and trauma-specific services
Eating disorder and nutrition services
Services for other co-occurring disorders, including access to psychological and pharmacological treatments
for mood and anxiety disorders
Children’s mental health services
Disability Services
Resources for learning disability assessments
Accommodations for specific disabilities
Services to accommodate illiteracy
Services to accommodate women receiving methadone treatment
Staff and Program Development
Strong female role models in terms of both leadership and personal recovery
Peer support
Adequate staffing to meet added program demands
Staff training and gender-competence in working with women
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Staff training and program development centered upon cultural/ethnic influences on parenting styles,
attitudes toward discipline, children’s diet, level of parenting supervision, and adherence to medical treatment
Flexible scheduling and staff coordination (Brown 2000)
Adequate time for parent–child bonding and interactions
Administrative commitment to addressing the unique needs of women in treatment
Staff training and administrative policies to support the integration of treatment services with clients on
methadone maintenance
Culturally appropriate programming that matches specific socialization and cultural practices for women

T REATMENT
C OCAINE

FOR

AND

S PECIFIC S UBSTANCE U SE D ISORDERS

M ETHAMPHETAMINES

For women who are dependent on cocaine and have young children, promising behavioral
treatments include contingency management (which provides immediate rewards such as vouchers
for abstinence), cognitive behavioral therapy, and the community reinforcement approach (which
promotes engagement in activities that can be rewarding alternatives to cocaine use) (Schottenfeld,
Moore, & Pantalon, 2011). One study found pregnant women who met criteria for cocaine abuse
were more likely to complete intensive outpatient treatment than traditional outpatient treatment,
although additional research is needed (Haug et al., 2014).
A randomized trial compared the community reinforcement approach with and without contingency
management to a 12-step facilitation program with and without contingency management among
cocaine-dependent women who were pregnant or had young children. Schottenfeld and colleagues
found no significant differences between community reinforcement and 12-step facilitation, but they
did find the contingency management approach to be associated with a significantly higher
proportion of cocaine-negative urine tests during treatment and more consecutive weeks of
documented abstinence from cocaine (Schottenfeld et al., 2011).
A study involving pregnant heroin- or cocaine-dependent pregnant women from a Baltimore SUD
treatment facility randomly assigned participants to usual care or to community reinforcement-based
treatment (RBT), which involves individual counseling plus support for housing, recreation, and
employment skills training that is contingent on abstinence. The authors found that RBT
participants remained in treatment longer, and their infants spent fewer days hospitalized after birth
(H. E. Jones, O’Grady, & Tuten, 2011).

O PIOIDS

AND

O PIATES

Opioid detoxification is not recommended during pregnancy, because withdrawal can lead to fetal
distress or death, and even medically supervised withdrawal is associated with a high rate of relapse
(ACOG & ASAM, 2012). Instead, women should continue to use methadone or buprenorphine
under a provider’s care. Methadone and buprenorphine are related compounds used in Medication
Assisted Treatment (MAT) that suppress and reduce cravings for opioids while preventing
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withdrawal symptoms (SAMHSA, 2015). In choosing between methadone and buprenorphine, one
consideration is that methadone may only be dispensed in daily doses from specific treatment
facilities, while only specially credentialed providers can prescribe buprenorphine. “Compared with
methadone clinics, the less stringent structure of buprenorphine treatment may make it
inappropriate for some patients who require more intensive structure and supervision,” ACOG and
ASAM note in a committee opinion (ACOG & ASAM, 2012). The need to visit a clinic daily may
also present logistical barriers to patients with childcare or transportation challenges.
While less research has been completed on buprenorphine than methadone for use during
pregnancy, the two appear to have similar effectiveness (Wisner et al., 2017). A review and metaanalysis of comparison studies found infants born to women who took buprenorphine were larger at
birth and less likely to be treated for NAS than those born to women who took methadone (Brogly,
Saia, Walley, Du, & Sebastiani, 2014). A randomized controlled trial that assigned 175 pregnant
women with opioid dependence to either methadone or buprenorphine found that the
buprenorphine-exposed infants required less NAS treatment and shorter hospital stays than
methadone-exposed infants; however, women in the buprenorphine group were more likely to
discontinue treatment, largely due to dissatisfaction (H. E. Jones et al., 2010).
A 2016 review and meta-analysis of studies comparing the two substances found a lower risk of
preterm birth and greater birthweight in buprenorphine-exposed infants, but concluded, “evidence is
currently insufficient to establish superior safety of either opioid agonist during pregnancy for all
maternal, fetal and child outcomes” (Zedler et al., 2016). Jones and colleagues recommend,
“Medication choices for each opioid-dependent patient during pregnancy need to be made on a
patient-by-patient basis, taking into consideration the patient’s opioid dependence history, previous
and current treatment experiences, medical circumstances and treatment preferences” (H. E. Jones,
Finnegan, & Kaltenbach, 2012).

A LCOHOL
Alcohol use and alcohol use disorders are common in the general population. Given the relatively
strong evidence of the negative effects of alcohol on a fetus and on the child, more research into
treatment programs that work for pregnant women should be prioritized.
For alcohol treatment in the general population, a combination of medication and psychosocial
therapy may be more effective than either form of treatment alone. Physicians are advised to refer
patients with alcohol use disorder for pharmacotherapy; case monitoring; individual, group, or
family/couples counseling and therapy; other psychosocial services, such as vocational counseling;
or mutual-help groups such as Alcoholics Anonymous (SAMHSA, 2010). FDA has approved the
medications Acamprosate, Disulfiram, Oral Naltrexone, and Extended-Release Injectable
Naltrexone to treat alcohol use disorder; all were classified as Category C for pregnancy under the
previous FDA labeling system, meaning women should not take them unless the benefits outweigh
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the risks. SAMHSA advises against using Disulfiram in pregnant women and recommends
Acamprosate for pregnant and nursing women with caution (SAMHSA, 2010).
Brief interventions for alcohol use disorder (AUD) have shown mixed levels of effectiveness in the
literature. One systematic review concluded brief interventions for AUD may increase abstinence
and decrease alcohol consumption during the pregnancy (Stade et al., 2009). Another systematic
review found that single-session face-to-face brief interventions positively affected the maintenance
of alcohol abstinence during pregnancy (Gilinsky, Swanson, & Power, 2011). However, the same
review noted that women who continue to drink during pregnancy may require more intense
intervention to reduce or eliminate alcohol consumption during pregnancy. Individual studies of
brief interventions for pregnant women have shown more specific results. In one study, women
who underwent brief interventions (10-15 minute sessions) were more likely to report abstinence
after the intervention and to have lower fetal mortality than their peers who only received screening
(O’Connor & Whaley, 2007). Chang and colleagues found brief interventions reduced alcohol
consumption most significantly in women who had a high consumption rate before the intervention,
and in women who had supportive partners (G. Chang et al., 2005).
Outpatient care for AUD is very common, and is typically delivered in once- or twice-weekly
sessions. Outpatient care is typically delivered through different counseling methods, including 12step facilitation, cognitive-behavioral therapy, motivational interviewing, contingency management,
or behavioral couples therapy (Haug et al., 2014). Although all have theory to support their
effectiveness, they have not been studied sufficiently in pregnant women with AUD. Inpatient
services and trauma interventions have also not been evaluated specifically in women with AUD
(Haug et al., 2014).

M ARIJUANA
Insufficient research is available regarding the treatment of pregnant women with cannabis use
disorder. For adults with a diagnosis of cannabis dependence, SAMHSA recommends Brief
Marijuana Dependence Counseling, a nine-session intervention program that includes elements of
motivational enhancement therapy, cognitive behavioral therapy, and case management (Steinberg et
al., 2005). Cannabis users tend not to seek treatment in traditional settings (Steinberg et al., 2005).
However, interventions have shown promise in producing significant, though modest, reductions in
marijuana use. One of the largest cannabis-focused studies, the Marijuana Treatment Project, tested
the effectiveness of using motivational enhancement therapy, cognitive behavioral therapy, and
individual counseling for cannabis users wishing to decrease use. The study showed that 13% of 450
participants who underwent a nine-week intervention were abstinent from cannabis at a nine-month
follow-up exam (Stephens, Babor, Kadden, & Miller, 2002). Another study with 291 participants
compared the effects of group-based cognitive behavioral therapy, shorter-term individual
counseling with motivational enhancement therapy, and no intervention (control). At a 16-month
follow-up, 29% and 28% of each treatment group reported being abstinent from cannabis in the last
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90 days. The control group was given the therapy treatment at four months, so no follow-up data
are available from the control group (Stephens, Roffman, & Curtin, 2000).

T REATMENT

FOR

P OSTPARTUM

AND

P ARENTING W OMEN

Women who stop substance use while pregnant are at high risk of relapse to substances of abuse in
the postpartum period (Gopman, 2014). This time presents many triggers for relapse in women
recovering from substance use disorders, including hormonal changes, sleep deprivation, and other
stresses and demands of parenting (Gopman, 2014; SAMHSA, 2009). A retrospective chart review
study of women enrolled in a substance abuse treatment program revealed that rates of postpartum
depression were higher in this population compared to non-users. Nearly one-third of the sample
had a history of depression before beginning the treatment program. The authors concluded that
their results support prior findings of depression being one of the largest predictors of postpartum
depression. Their recommendation was that doctors perform routine screenings for perinatal and
postpartum depression in their patients who use substances, as they are at higher risk (A. Holbrook
& Kaltenbach, 2012).
Studies have found that deaths among women who are pregnant or who have recently given birth
are often due to overdoses. This may be related to biological factors, drug potency, or other issues.
A California study that followed pregnant or parenting women admitted to substance treatment
programs between 2000 and 2002 found that 194 of the 4,447 study participants had died by the end
of 2010, which translated to a mortality risk more than eight times higher than that of women of
comparable ages in the general population. Overdose was the most common cause of mortality,
accounting for 29% of the deaths (Hser, Kagihara, Huang, & Messina, 2012). An analysis of deaths
occurring in Philadelphia women during or in the one year following pregnancy found that 18 of the
85 deaths, or more than one-fifth, were due to drug overdoses (Mehta, Bachhuber, Hoffman, &
Srinivas, 2016). An examination of 385 deaths linked to toxicology reports in Florida women during
or in the year after pregnancy found 47, or 12%, were due to overdoses, with 70% of the overdoses
caused by prescription drugs (Hardt et al., 2013).
An analysis of responses to the 1996-1998 National Household Survey on Drug Abuse found that
93% of those who were using illicit drugs when they recognized their pregnancies reported being
abstinent by the third trimester; however, due to post-pregnancy relapse, the net pregnancy-related
reduction in illicit drug use was only 24% (Ebrahim & Gfroerer, 2003). Among women enrolled in a
study that compared psychological treatments for substance use (heavy use of tobacco or alcohol, or
any use of marijuana or cocaine) in pregnancy, 80% of those who were abstinent in the last month
of pregnancy resumed use of at least one substance in the two years after delivery, particularly within
the first three months (Forray & Foster, 2015).
SAMHSA’s Treatment Improvement Protocol on treatment for women with substance abuse
recommends that services clients used prenatally should be continued, if not intensified, during the
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postpartum period. The protocol recommends relapse prevention education, with an emphasis on
identifying potential triggers and planning for appropriate responses, in the context of a full program
of recovery activities. The protocol notes, “Alumnae groups and in-home visitation programs have
assisted women with relapse prevention and family preservation” (SAMHSA, 2009). However, many
SUD treatment programs are not tailored to pregnant and postpartum women, and a minority of
programs offer childcare and other such supports that can make them accessible for women in the
postpartum period. (See “Accessibility of Treatment” section, page 28.)
Postpartum women may also be concerned about breastfeeding their infants while using substances,
including methadone or buprenorphine as part of opioid-assisted therapy. ACOG and ASAM note
that breastfeeding is compatible with opioid-assisted therapy (ACOG & ASAM, 2012). The
American Academy of Pediatrics (AAP) also advises that women on methadone maintenance may
still breastfeed, regardless of dosage (American Academy of Pediatrics, 2012). Breastfeeding’s skinto-skin contact may diminish some neonatal abstinence syndrome and motivate mothers to maintain
abstinence (Gopman, 2014). AAP advises, “Street drugs such as PCP (phencyclidine), cocaine, and
cannabis can be detected in human milk, and their use by breastfeeding mothers is of concern,
particularly regarding the infant’s long-term neurobehavioral development and thus are
contraindicated” (AAP, 2012). AAP recommends women limit alcohol consumption (e.g., two
ounces of liquor, eight ounces of wine, or two beers) and wait two hours after ingestion to
breastfeed (AAP, 2012).

U SE

OF

T REATMENT S ERVICES

BY

P REGNANT W OMEN

The existing public data on the numbers of pregnant women who need, seek, or receive SUD
treatment services are sparse and insufficient.
SAMHSA’s reports on findings from its National Survey on Drug Use and Health (NSDUH)
contain limited data on pregnant women and treatment, though their statistics on women and
treatment give an indication of the gap between treatment needs and availability. According to
SAMHSA, 7.7 million women or girls age 12 and older met DSM-IV criteria for substance
dependence or abuse in 2014, but only 1.4 million of them reported receiving substance use
treatment in any form (including self-help groups). Of women and girls age 12 and older, only 11%
of those who needed treatment received it from a specialty facility, a category that includes drug and
alcohol rehabilitation facilities, mental health centers, or inpatient hospital units. It is worth noting
that not all of those who met the criteria for needing treatment perceived a need for treatment;
among those who needed but did not receive treatment, 92% did not perceive a need for treatment
(Center for Behavioral Health Statistics and Quality, 2015b).
There are limited data on the number of pregnant women needing substance use treatment. In an
analysis of 2002-2006 data from the NSDUH, Terplan and colleagues (2012) found that pregnant
women were less likely than non-pregnant women to report alcohol or illicit drug use during the
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previous month (14% vs. 51%), but among those who did report substance use, pregnant women
were significantly more likely to meet the DSM-IV criteria for substance abuse or dependence (30%
vs 18%). The authors note that this finding supports the observation that although women often
reduce or eliminate substance use while pregnant, those who continue to use substances during
pregnancy are likely to do so because they have more problematic use that is harder to address
without treatment. There was no significant difference between groups in the likelihood of receiving
treatment for abuse or dependence (Terplan et al., 2012).
Although medication-assisted therapy (MAT) using methadone or buprenorphine is the standard of
care for opioid use disorders in pregnancy, many pregnant women who could benefit from MAT do
not receive it. Martin and colleagues (2015) found that substance abuse treatment facilities served
substantially more pregnant women reporting prescription opioid abuse in 2012 than in 1992 (6,087
in 2012, up from just 321 in 1992). However, the percentage of treated pregnant women who
received medication assisted treatment — the standard of care for opioid treatment during
pregnancy — remained disconcertingly low, at 37% in both 2008 and 2012. The low rate of MAT
use reflects lack of access to such therapies in general, the authors concluded (Martin, Longinaker, &
Terplan, 2015). Similarly, an analysis of data on 2012 substance use treatment episodes across the
U.S. by Angelotta and colleagues found that slightly less than half of pregnant women with opioid
use disorders received MAT (Angelotta, Weiss, Angelotta, & Friedman, 2016).

T OO F EW P ROVIDERS
For women with opioid use disorders, methadone may only be dispensed in daily doses from
specialized treatment facilities (methadone clinics), while physicians can prescribe and dispense
buprenorphine from their offices only if they complete eight hours of training and receive SAMHSA
approval of a waiver (SAMHSA, 2016a). In the first year of practicing with a waiver, physicians may
prescribe to as many as 30 patients; after that, they may request a revised waiver to increase their
patient limit. The second, higher limit increased in mid-2016 from 100 patients to 275 (Medication
Assisted Treatment for Opioid Use Disorders, 2016). While this higher limit is welcome to
physicians who had reached their limits and had to turn patients away (ASAM Staff, 2016), it does
not address the issue of the number of physicians who are able to provide buprenorphine, particular
in rural or other underserved parts of the country.
In February 2017, SAMHSA’s website showed that fewer than 25,000 physicians had waivers to
prescribe buprenorphine to up to 30 patients, while fewer than 3,000 could prescribe to 275
(SAMHSA, 2017). Studies have found that 44-66% of physicians with waivers actually prescribe
buprenorphine. An analysis of 2012 data found that opioid abuse or dependence rates were higher
than buprenorphine treatment capacity rates in 48 states (Maine and Vermont were the exceptions)
(C. M. Jones, Campopiano, Baldwin, & McCance-Katz, 2015). A study of buprenorphine treatment
availability in Washington State found the lowest provider-to-population ratio in rural areas
(Kvamme, Catlin, Banta-Green, Roll, & Rosenblatt, 2013).
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C ARE

FOR I NCARCERATED

P REGNANT W OMEN

Women account for a growing share of the population of U.S. prisons and jails, and approximately
9,000 adult women are pregnant when entering federal and state correctional facilities and local jails
each year.4 Among women in state prisons, 74% of those with a mental health problem met criteria
for substance abuse or dependence, as did 54% of those without a mental health problem (James &
Glaze, 2006). A study of women in county jails found that 53% met the criteria for substance use
disorder, and 20% had both a SUD and serious mental illness (Nowotny, Belknap, Lynch, &
DeHart, 2014). In a survey of the medical directors of state and federal Departments of Corrections,
only 55% reported that their prison systems make methadone available to inmates, and only 14%
offer buprenorphine. For treatment following release, 45% reported that they provide referrals to
community-based methadone clinics, and 29% give referrals to providers who prescribe
buprenorphine (Nunn et al., 2009).
Incarcerated pregnant women face substantial challenges to obtaining both appropriate prenatal care
and treatment for substance use disorders (Gopman, 2014). They typically face inadequate nutrition,
compromised rest, and minimal psychosocial support and education. Separation from children can
cause intense grief and exacerbate existing mental health conditions. Some prisons require that
women be shackled or otherwise restrained while in labor or giving birth, and this can amplify
distress (Ferszt & Clarke, 2013). Women who are pregnant upon release from a correctional facility
may face interruptions in prenatal care (Gopman, 2014).
In addition to improving care for incarcerated women, correctional systems can avoid increasing
pregnant women’s risks of poor outcomes by not incarcerating women solely based on illegal
substance use, if the woman is pregnant. ASAM (2011) warns, “Incarceration of pregnant women as
a means of preventing fetal exposure to alcohol and other drug use may compromise both maternal
and fetal health and inhibit the pregnant woman’s opportunity to receive effective treatments to
address her long-term recovery from her substance-related disorder” (ASAM, 2011).

4

In 2004, the percentage of incarcerated women who are pregnant at intake was 4% in state prisons, 3% in federal
prisons (Maruschak, 2008), and 5% in jails (Maruschak, 2006). Applying these percentages to the 2014 correctional
population figures (97,189 women in state correctional facilities and 14,169 women in federal facilities; Carson, 2015)
suggests more than 4,000 women are pregnant when they enter state or federal correctional facilities. Another 98,600
women were in jail in 2012 (Minton & Zeng, 2015), of whom nearly 5,000 would likely have been pregnant. The
estimated total of 9,000 incarcerated pregnant women does not include pregnant adolescents in juvenile detention
facilities.
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C URRENT P OLICY I SSUES
Substance use by pregnant women brings together two areas of social policy that have each proven
highly controversial over the last several decades. Pregnant women – particularly women of color
and poor women who are most affected by the mechanisms of state control – have been subjected
to a clash of forces where the war on drugs intersects with the protracted battles over abortion and
reproductive autonomy. Although alcohol policy stands apart from the war on drugs in significant
ways, when it comes to pregnant women, there are substantial commonalities that extend across
both alcohol and other criminalized drug use.
Punitive measures associated with violating laws prohibiting possession of controlled substances
apply across the population, such as fines, loss of a driver’s license, and incarceration. In addition,
laws and policies that subject pregnant women who use substances to extra scrutiny have
ramifications related to parenting rights and responsibilities, including court-ordered separation of
mothers from their children. When a pregnant woman’s drug test results or evidence of drug or
alcohol exposure in a newborn are used in child welfare proceedings, the stated reason may be
protection of the child; however, there is no requirement to show that the woman’s use of a drug
has caused actual or potential harm to the child (Miranda et al., 2015). Furthermore, a diagnosis of
NAS does not equal harm or abuse to a child; for an infant born to a woman who was prescribed
MAT during her pregnancy, NAS is a side effect of a medication that was being used appropriately
to treat a SUD (Finnegan, 2016).
The laws and policies that apply this pregnancy-specific scrutiny to a woman’s substance use have
critical implications for questions that are central to debates over pregnant women’s rights, including
what interest, if any, the state has in protecting a fetus and at what point in pregnancy; and whether
there is any legal, public health, or other justification for treating the interests of a pregnant woman
as distinct from the interests of her future child.
Research reviewing the history of social policy related to drug use notes, “Once the fetus became the
central protagonist there was a significant shift in social perception. The concept of harming the
fetus by using drugs during pregnancy resulted in sanctions by both the criminal justice system and
the child protective system” (Lester et al., 2004). Concerns about harm to the fetus and future
children has also been a powerful motivator behind laws aimed at consumption of alcohol by
pregnant women. A review of recent CDC health guidelines for pregnancy and alcohol, for example,
cited critics’ observation that “the guidelines focus entirely on the well-being of the developing fetus
while disregarding women’s rights as autonomous beings […] and ignoring structural factors that
contribute to fetal exposure to alcohol.” This review also notes that, as with drug policy, the
pressures to control pregnant women’s drinking are greatest for low-income women and women of
color (Seiler, 2016). The inequitable impact on low-income women and women of color makes it
more difficult to ensure that these groups receive access to substance use treatment, prenatal care,
and human rights.
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The tension between efforts to address the intersection of substance use and pregnancy with
punitive measures and those that focus on improving access to evidence-based care and treatment
for pregnant women and infants is at the center of many current state and federal policy debates on
substance use. Laws and policies discussed here include measures on education about the dangers of
substance use while pregnant; testing of pregnant women and infants for indicators of drug
exposure and reporting of results; criminalization and punishment of pregnant women for use of
substances; access to treatment for substance use disorders; and increased investment in research to
build the evidence base.
The social policy implications of these state efforts to address problems and concerns related to
pregnant women and substance use, however, go beyond education, testing, prosecution, and
treatment. These laws and policies have a far-reaching impact in the lives of women, children,
families, and communities – not only on access to care and health outcomes, but also on family
formation and separation, housing, education, voting rights, and employment.
These policies are implemented in criminal justice and child welfare systems where the ongoing
legacy and reality of racism undermines the even-handed application of laws and policies. Thus,
punitive measures have a disparate impact by race and ethnicity, with people of color
disproportionately experiencing the most serious harmful effects, including family separation and
incarceration. Describing the full cascade of consequences that flows from the laws and policies
discussed below is beyond the scope of this paper; however, we recognize that the state’s increased
scrutiny of pregnant women’s decisions and behavior may have effects that extend long past the
duration of a pregnancy.

E DUCATION
Public education about the dangers of alcohol consumption during pregnancy is the most broadly
visible manifestation of laws and policies targeting pregnant women’s substance use. The Alcoholic
Beverage Labeling Act is a federal law (27 U.S. Code § 215) requiring that the labels of all alcoholic
beverages sold or distributed in the United States include the following language, under the heading
GOVERNMENT WARNING: “According to the Surgeon General, women should not drink
alcoholic beverages during pregnancy because of the risk of birth defects.” In addition, 24 states
have established laws mandating that warning signs about the risks associated with drinking during
pregnancy be posted in places where alcoholic beverages are sold and in healthcare facilities treating
pregnant women (Alcohol Policy Information System, 2016).
These laws are designed to inform the public, not restrict or control behavior; they do not require or
authorize establishments that post the signs or individuals employed by those establishments to
prevent pregnant women from purchasing or consuming alcoholic beverages, but some businesses
and individuals have attempted to take that next step. In 2016, New York City responded to reports
of such pregnancy prohibition policies by issuing guidelines stating that restaurants and bars that
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refuse to fill alcoholic beverage orders from pregnant women may be guilty of pregnancy
discrimination under the City’s Human Rights law. A lawyer working for a trade group representing
bars in New York argued that the City’s new guidelines make things difficult for people who take
seriously the warnings about the dangers of alcohol consumption during pregnancy that state law
requires the bars to post (McPhate, 2016).

U NINTENDED P REGNANCY

AMONG

S UBSTANCE U SE D ISORDER T REATMENT P ATIENTS

One strategy to reduce negative outcomes from substance use during pregnancy is to ensure that
women who use substances have access to high-quality family planning services that enable them to
avoid unintended pregnancies. Women undergoing treatment for SUDs have reported that family
planning is a concern (Robinowitz, Muqueeth, Scheibler, Salisbury-Afshar, & Terplan, 2016). Women
with SUDs are less likely to use contraception (Terplan, Hand, Hutchinson, Salisbury-Afshar, & Heil,
2015) and more likely to have an unintended pregnancy (Heil et al., 2011) than their non-using peers.
Women who use drugs are also more likely to rely on condoms for contraception rather than more
effective methods (including birth control pills, injectable contraception, IUDs, implants, and tubal
ligation) (Terplan, Hand, et al., 2015). In focus groups and interviews with providers and women
clients from three Baltimore SUD treatment centers, Robinowitz and colleagues found that women
were open to using contraception and receiving family planning education and services while receiving
SUD treatment, but that they had difficulty accessing services while in treatment (Robinowitz et al.,
2016). In addition to improving access to family planning services for the population, including family
planning in SUD treatment programs could help clients avoid unintended pregnancies.
Effective preventive strategies would ensure that access to contraception and family planning
services be provided through programs that are fully voluntary, non-coercive, and grounded in
meeting women’s own needs and preferences. Although some forms of contraception such as longacting reversible contraceptive (LARC) methods are more effective at preventing pregnancy, the
decision to use a LARC must be made between a woman and her healthcare provider without
pressure to discourage the woman from becoming pregnant (Strasser, Borkowski, Couillard, Allina,
& Wood, 2016). Ideally, family planning services would be an integrated part of a woman’s
healthcare that also addresses any psychological challenges or mental health issues and includes
prenatal care once a woman is ready to become pregnant. In one recent study, the majority of
participants (83% of women and 58% of men) in a substance use disorder treatment programs said
they were more likely to use contraception if it were available through the treatment program
(Terplan, Lawental, Connah, & Martin, 2016). Family planning should also include services to help
women who want to have children in the near future achieve healthy pregnancies and births.
One program that emphasizes contraception to prevent substance-exposed pregnancies is
CHOICES, an intervention using brief motivational interviewing with women who could become
pregnant and who consume more than five drinks in a day or more than eight drinks per week. In a
randomized trial at sites in Florida, Texas, and Virginia, participants received either information only
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or information plus five counseling sessions — four motivational interviewing sessions and one
contraceptive counseling visit with a healthcare provider. Women in both groups had reduced binge
drinking after nine months, with a larger proportion of the intervention group reporting no binge
episodes in the previous 90 days (58%, vs. 47% of the control group). At nine months, 57% of the
intervention group and 39% of the control group reported effective use of contraception (using
contraception consistently and according to published guidelines for the use of that method) during
vaginal intercourse over the past 90 days (Floyd et al., 2007).
Access to abortion care is also an important aspect of healthcare services for pregnant women who
have substance use disorders. Women who use substances and do not want to be pregnant may be
delayed in seeking termination because they are unaware of the pregnancy, because they lack access
to abortion services, or because they face financial barriers to care. On the other hand, women must
not be coerced into having an abortion by arrest or threat of arrest, or pressured to have an abortion
based on unsupported beliefs about the harm of drugs they might have taken during pregnancy.
Rather, women should receive accurate information to help them characterize and understand the
risks of any substances they have used and whether any future actions can ameliorate the effects, as
well as non-directive options counseling and referral to appropriate providers and other supports.
One recent trend in state abortion restrictions are laws that ban abortions after 20 weeks’ gestation.
These laws are especially problematic for women who do not realize they are pregnant until several
weeks have passed and encounter delays when they decide to seek abortion care. Studies that
compared women who received abortions in the second trimester to those who received them in the
first trimester have found that those receiving the later abortions are more likely to use drugs and/or
alcohol regularly (Drey et al., 2006; Foster & Kimport, 2013). The impacts of these laws can be
compounded by other state laws that directly or indirectly add delays, either through mandatory
waiting periods before receiving an abortion or by prohibiting Medicaid or private insurers from
covering abortion services.
The purported concern for maternal or fetal health that state policymakers profess when enacting
restrictions on abortion access does not always appear to drive enactment of policies that help
pregnant women with substance use disorders obtain treatment. As of February 2017, 19 states had
created or funded programs specifically targeted at pregnant women, and 16 plus the District of
Columbia require that pregnant women receive priority access in general programs. Missing from
the list of states that have taken one or both of these steps are several states with laws that restrict
abortion access. For instance, South Dakota and Texas have all passed laws banning abortions after
20 weeks post-fertilization and do not allow Medicaid coverage of most abortions. These states also
consider substance abuse during pregnancy to be child abuse, but have not created targeted
treatment programs for pregnant women or granted them priority access to treatment (Authors’
analysis of data from Guttmacher Institute, 2017a, 2017b, 2017c).
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P OLICIES D ESIGNED

TO I NCREASE

A CCESS

TO

T REATMENT

There are both federal and state laws intended to make it easier to get substance use disorder
treatment by reducing cost barriers to services and increasing the availability and accessibility of care.
The Affordable Care Act (ACA) resulted in a dramatic expansion of coverage for treatment, and the
Mental Health Parity and Addiction Equity Act requires that coverage for substance use treatment
cannot have more restrictions (such as cost-sharing or visit limits) than other medical coverage (U.S.
Department of Labor, 2010). Additionally, policymakers have attempted to use funding incentives to
increase the availability of treatment that meets the needs of pregnant and parenting women
(CAPTA Reauthorization Act, 2010).
The ACA requires all health insurance plans offered in its marketplaces to cover substance use
disorder treatment. The law’s ban on imposing pre-existing condition exclusions and on setting
yearly or lifetime dollar limits on coverage apply to substance use disorder conditions and services.
The ACA requirement to cover substance use disorder treatment also applies to the benefits
available to people who become eligible for Medicaid as a result of the law’s expansion of that
program. For people insured through traditional Medicaid, coverage of substance use disorder
treatment is optional and varies by state.
However, while some state Medicaid programs ease access by including treatment medications, such
as methadone and buprenorphine, on their preferred drug lists, other states require steps such as
prior authorization that can create barriers to use. In a 2014 report on Medicaid policies in the 50
states and District of Columbia, SAMHSA reported that only 31 include methadone on their
preferred drug list; 13 require prior authorization to obtain it, and 10 limit the quantity beneficiaries
can get. Availability of buprenorphine was even more limited, with 48 Medicaid programs requiring
prior authorization and 11 imposing lifetime limits — a move incompatible with appropriate
treatment of a chronic disease (SAMHSA, 2014a).
Medicare does pay for treatment of alcoholism and substance use disorders for disabled women who
may be pregnant, in both inpatient and outpatient settings, though there are some limits on the
coverage (Medicare Interactive, n.d.).

L IMITS

TO

A CCESS

Even with such coverage, however, people seeking treatment may have difficulty using private
insurance, Medicaid, or Medicare to pay for services because many SUD treatment programs do not
accept those payment options. According to an annual census of substance abuse treatment facilities
conducted by SAMHSA, as of 2014, only 33% accepted Medicare, 60% accepted Medicaid, and 67%
accepted private insurance (SAMHSA, 2013). A substantial percentage of programs offer treatment
without charge to people who cannot afford to pay: 20% of programs operated by private, for-profit
facilities reported this option, and it was more common at those operated by non-profit
organizations and federal, state, local, and tribal governments (SAMHSA, 2013).
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Beyond cost, access is also determined by availability of appropriate programs. Historically, few
programs were designed to address the needs of pregnant and parenting women, but there have
been some advances in recent years. Federal grants currently are available to public and private nonprofit programs that provide treatment for substance use disorders to pregnant and postpartum
women. States that give pregnant women priority access to treatment programs are eligible for
additional allocations of grants for prevention and treatment of substance abuse (Alcohol Policy
Information System, 2015c). Programs funded through these grants may be residential or provide
outpatient services from residential facilities, and if residential they must allow the minor children of
a woman to reside with her if she requests it. To be eligible for these grants, a program must provide
individual, group, and family counseling for substance use disorders, as appropriate, to each woman
admitted to the program. They must also make available a set of supplemental services that includes,
among others: prenatal and post-natal healthcare; pediatric healthcare, counseling and
comprehensive social services for the infants and children of women admitted; therapeutic,
comprehensive childcare during the times when a woman is unavailable due to her own treatment
services; parenting training; and reasonable efforts to support and preserve the family unit, including
family reunification with children in kinship or foster care arrangements, where safe and appropriate.
Additionally, programs that receive these federal grants must be operated at a location that is
accessible to low-income pregnant and postpartum women, and services must be provided in the
language and the cultural context that is most appropriate (CAPTA Reauthorization Act, 2010).
In 19 states, there are now drug treatment programs that are specifically targeted to pregnant
women, and 12 states give pregnant women priority admission to general drug treatment programs
(National Association of State Alcohol and Drug Abuse Directors, 2016). To date, we have found
little documentation on how priority access is determined. Additionally, four states (Iowa, Kansas,
Missouri, and Oklahoma) have taken the step of prohibiting drug treatment programs that receive
public funds from discriminating against pregnant women (Guttmacher Institute, 2016a). In 17
states, there are laws requiring that pregnant and postpartum women who abuse alcohol be given
priority access to treatment (Alcohol Policy Information System, 2015c).
In July 2016, Congress passed the Comprehensive Addiction and Recovery Act (CARA), which
specifically authorizes grants to state agencies to carry out pilot programs for non-residential
treatment of pregnant and postpartum women with SUDs. It also aims to make medication-assisted
treatment for SUDs more accessible by expanding prescribing authority for buprenorphine, which
was previously limited to specially certified physicians, to nurse practitioners and physician assistants
who are certified and receive a waiver (CARA, 2016). It misses the opportunity to improve access
for pregnant patients who are receiving care from nurse midwives, however, because it does not
include them. If Congress goes on to provide funding for the programs CARA authorizes, it will
significantly expand access to addiction treatment services and overdose reversal medications.
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P OLICIES C REATING B ARRIERS

TO

T REATMENT

Policies designed to make treatment accessible are not sufficient, however, to overcome the
substantial barriers erected by mandated testing and reporting or by prosecution practices. Research
has identified pregnant women’s fears of prosecution and loss of child custody as a significant
barrier to bringing women into treatment programs for substance use (Finkelstein, 1994; Howell,
Heiser, & Harrington, 1999). The threat of criminal charges or removal of children based on
pregnancy and substance use can interfere with women’s ability to receive timely, high-quality care
for their pregnancies, potentially negatively affecting the health of infants and children born to those
women who were not able to get prenatal care.
The impact of removing children from women who have SUDs into foster care needs further
research, especially given the chronic underfunding of many social services. Current evidence on the
effectiveness of foster care in improving child outcomes is mixed. Stability for foster children can
help predict their behavioral well-being (Rubin, O’Reilly, Luan, & Localio, 2007). One study found
that “children assigned to investigators with higher removal rates are more likely to be placed in
foster care themselves, and they have higher delinquency rates, teen birth rates, and lower earnings,”
(Doyle, 2007) and noted children (especially older children) fare better when they can remain at
home (Doyle, 2007). However, another study found that once children were removed from the
home, the ones who reunified with their families had higher rates of self-destructive behavior,
substance use, and problems with law enforcement than the children who did not reunify (Taussig,
Clyman, & Landsverk, 2001). Early intervention work has shown promise in improving permanent
placement outcomes in younger children (Fisher, Burraston, & Pears, 2005), but is not a standard
requirement of foster care.

R ESEARCH

ON

P OLICY B ARRIERS

TO

P RENATAL C ARE

AND

T REATMENT

Researchers can find it challenging to isolate the effects of substance use and related punitive
measures on women’s use of prenatal care because women with substance use disorders often
experience multiple conditions (poverty, limited transportation, depression, housing instability, etc.)
that are also associated with receiving less prenatal care than advised. Nonetheless, findings from
accumulating research suggest punitive measures may interfere with women’s receipt of timely, highquality care. Early prenatal care is recommended for the best possible maternal and infant outcomes
(CDC, 2011), and policies that have the effect of discouraging women from promptly receiving
prenatal care can result in missed opportunities to resolve concerns and connect women to
appropriate services.

I MPACT

ON

P RENATAL C ARE

Schempf and Strobino (2009) analyzed medical records, urine toxicology screens administered at
delivery, and postpartum surveys from 812 low-income women who delivered at the Johns Hopkins
Hospital in Baltimore. They found that women who used cocaine and opiates during pregnancy
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were more than six times more likely than those not using drugs to have received no prenatal care or
only one prenatal care visit, and that “fear of being reported to the police or child welfare authorities
was related strongly to a lack of prenatal care” (Schempf & Strobino, 2009).
Roberts and colleagues conducted interviews and focus groups with a racially and ethnically diverse
sample of 38 low-income pregnant and parenting women who used alcohol and/or drugs. In the
county where the study took place, all public prenatal providers conducted universal alcohol and
drug screening with supplementary urine testing. Participants cited several reasons for attending
prenatal care, including “to make sure the baby’s okay,” obtaining prenatal vitamins, reassurance of
the baby’s health, and doing something right to compensate for effects of drug use (Roberts & Pies,
2011). They also, however, consistently described feeling “guilt” or “shame” upon being identified
as using substances during pregnancy, and many feared provider reactions and viewed providers as a
source of punishment rather than protection (Roberts & Pies, 2011).
Some women who stopped using drugs during pregnancy told researchers that urine tests motivated
them to abstain from drug use, but some delayed starting prenatal care, skipped appointments, used
alcohol instead of other drugs, and used other women’s urine in order to avoid the consequences
they feared (Roberts & Nuru-Jeter, 2010). The consequences they reported worrying about included
“being arrested, forced to have an abortion, terminated from a prenatal care program, and reported
to CPS” (Roberts & Nuru-Jeter, 2010). The authors report that “most women feared that attending
prenatal care while using drugs would lead to CPS reports and losing their children” (Roberts &
Pies, 2011). A few attended prenatal care despite this fear, because they prioritized their babies’
health or aimed to build a track record that would increase their chances of keeping their babies and
reuniting with children already removed. Most of the participants, however, either avoided prenatal
care or attempted to stop using drugs before attending – and in some cases, this resulted in women
delaying prenatal care entry until their third trimester or delivering without prenatal care at all
(Roberts & Nuru-Jeter, 2010; Roberts & Pies, 2011).
Participants in this study also described several barriers to prenatal care that are common among
low-income women regardless of substance use, including lack of transportation and health
insurance, financial barriers, homelessness, and bureaucratic barriers to insurance and appointment
scheduling. Some women noted ways in which drug use could exacerbate these barriers or make it
harder to resolve them (Roberts & Nuru-Jeter, 2010).
Similarly, in interviews with 30 pregnant or recently pregnant Midwestern women who used
substances while pregnant, Stone found that the most common strategy reported for avoiding
detection of substance use was avoidance of care. In addition, some participants hid their
pregnancies or isolated themselves from friends, family members, or others who they feared might
report their substance use to authorities (Stone, 2015).
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I MPACT

ON

T REATMENT

In interviews with pregnant women who used marijuana before or during their pregnancies, Jarlenski
and colleagues (2016) found dissatisfaction with social workers who focused on punitive measures –
namely, involvement of the child welfare agency if women tested positive for substance use upon
delivery – rather than explaining the potential effects of marijuana use on infants’ health or offering
resources to assist with quitting. The authors report, “Several women indicated that knowledge of
specific health effects would have a powerful impact on their decision to stop marijuana use in
pregnancy. In contrast, information about legal consequences seemed to motivate women to have a
‘clean’ urine test at delivery rather than consider the health consequences of perinatal marijuana use
for themselves or their infants” (Jarlenski, Tarr, Holland, Farrell, & Chang, 2016).
Some recent research with pregnant women who have opioid disorders suggests, not surprisingly,
that in states with laws or policies allowing them to bring either criminal or civil charges for child
neglect or abuse against women who use substances during pregnancy, women with opioid use
disorders are less likely to receive appropriate care. Angelotta and colleagues found that women were
less likely to receive medication-assisted treatment (MAT) if their states had prenatal child abuse
laws. The authors also note, “Methadone maintenance is not covered by Medicaid in the majority of
states with prenatal child abuse laws, compounding the problem of access to the standard of care
treatment” (Angelotta et al., 2016). In states without prenatal child abuse laws and with Medicaid
coverage of methadone, 63% of pregnant women received MAT; in states with prenatal child abuse
laws and no Medicaid coverage of methadone, just 19% did. The authors urge: “Given that the
ostensible purpose of laws that allow pregnant women to be charged with child abuse for illicit drug
use in pregnancy is to encourage substance abuse treatment and reduce maternal and fetal harms and
these laws were associated with lower use of the standard of care, the utility of prenatal child abuse
laws should be reconsidered by state policymakers” (Angelotta et al., 2016).

M ANDATORY T ESTING

AND

R EPORTING

In keeping with the findings of this social science research, medical experts warn about the harmful
effects of mandatory testing or reporting of substance use during pregnancy. ACOG and ASAM
both oppose requirements for mandatory testing or reporting of substance use by pregnant women.
In order to preserve the physician-patient relationship, ASAM urges “laws or regulations should not
require physicians to violate confidentiality by reporting their pregnant patients with current or past
history of substance use to legal authorities and/or child welfare services in the absence of evidence
of child abuse or neglect” (ASAM, 2011). ACOG warns that such laws “may unwittingly result in
pregnant women concealing substance use from their obstetricians or even forgoing prenatal care
entirely” (ACOG, 2015). Universal lab testing for substance use is counterproductive because
concealing use is preferable to opting out of prenatal care.
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F EDERAL

AND

S TATE L AWS

ON

T ESTING
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R EPORTING

Despite the conclusions of research in this area and the opposition of medical experts, policymakers
often look to testing and reporting laws as a solution when faced with concerns about how
substance use may harm infants. There are both federal and state laws encouraging use of testing
and reporting of substance use during pregnancy.
In 2003, Congress amended the federal Child Abuse Prevention and Treatment Act (CAPTA), the
program that awards federal grants to states for their child protective services systems, to make a
state’s eligibility for those funds contingent on adoption of policies and procedures intended to
address the needs of infants “identified as being affected by illegal substance abuse or withdrawal
symptoms resulting from prenatal drug exposure.” To be eligible to receive a CAPTA grant, a state
must have policies and procedures in place for providers involved in the delivery or care of such
infants to notify child protective services, to make referrals for appropriate services, and to develop
a plan of safe care for those infants. The law also states, however, that the requirement for
notification of child protective services does not establish a definition in federal law of child abuse
and does not require prosecution. This is important because, while lawmakers included this
provision in a statute that addresses child abuse, medical experts agree that withdrawal symptoms in
an infant are not evidence of harm or abuse by the mother.
Some states already had such laws in place prior to 2003, but CAPTA created a financial incentive to
establish these policies, though it did not provide states with additional funds for the services they
assert that children affected by maternal drug use will need. Critics of that direction have
acknowledged that the author of the provision “had the laudable goal of ensuring that children
receive necessary services” but observe that the policy requires providers to participate in a reporting
practice that pregnant women may experience as punitive (Weber, 2007). This has several
consequences that raise concerns: it may compromise the relationship between the provider and the
pregnant patient that is needed to address substance use problems, if they exist; the opportunity for
intervention that it offers occurs too late, after the optimal time has passed to protect the fetus’s
health; and “it promotes the unproven theory that instituting coercive measures after the child’s
birth will produce a lasting ameliorative effect on the health of drug dependent women and their
children” (Weber, 2007).
The reporting provision of CAPTA has also been criticized as unsuccessful on its own terms by
those who point out that it fails to ensure the safety of children because the law does not provide
states with specific standards for substance exposure screening or assessment of substance-exposed
infants. As a result, states have interpreted the provision differently, and there is considerable
variation in their protocols for determining whether an infant has been exposed to drugs and in the
actions they require providers to take when a drug exposure is identified. In an ACOG Committee
Opinion discussing the role of the obstetrician-gynecologists in reporting substance use during
pregnancy, the authors remark on the differing standards, noting that “South Carolina relies on a
single positive drug test result, Florida mandates reporting infants that are ‘demonstrably, adversely
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affected’ by prenatal drug exposure, and in Texas, an infant must be ‘addicted’5 to an illegal
substance at birth” (ACOG, 2015).
In four states – Iowa, Kentucky, Minnesota, and North Dakota – healthcare professionals are
required to test infants for prenatal drug exposure if they suspect that the woman who gave birth
used drugs while pregnant (Miranda, Dixon, & Reyes, 2015). In all of those states except Kentucky,
and in 15 other states, healthcare professionals must report as civil child abuse what lawmakers have
termed “drug abuse” by a pregnant women (Guttmacher Institute, 2016b).

B OX 8. D EFINING C HILD A BUSE
Though Congress explicitly declined to define a test result from a pregnant woman or new mother
showing substance use as child abuse, there are 18 states where substance “abuse” during
pregnancy is considered child abuse under the state’s civil child welfare laws. In certain states,
being pregnant and using a controlled substance may result in a criminal child abuse conviction.
And even where it is not treated criminally, in states where a positive drug test can be used as
evidence in civil child welfare proceedings it may have very serious repercussions, including
separation of the child from the parent.
In Indiana, the law requiring drug testing and reporting applies only to women and infants who are
eligible for Medicaid, making the targeting of poor women explicit in statute. Research findings of
racial disparities in reporting of substance use during pregnancy to child welfare authorities
(Chasnoff, Landress, & Barrett, 2012; Roberts & Nuru-Jeter, 2012) suggest that, even where there is
no statutory focus on a sub-population, the impact of these laws falls more heavily on women of
color. On the other end of the spectrum, seven states actually prohibit the use of prenatal screenings
or toxicology tests in criminal prosecution of a woman for causing harm to a fetus or child (Alcohol
Policy Information System, 2015b).
To address concerns about unauthorized punitive responses to drug use by pregnant women,
Tennessee established the Safe Harbor Act in 2013, with the stated intention of encouraging
pregnant women with prescription drug use problems to seek treatment early in their pregnancies.
It promises to give pregnant women priority spots in drug treatment programs and protects a
woman’s parental rights if she enters treatment and remains in compliance with both treatment and
prenatal care throughout her pregnancy. The limited availability of appropriate drug treatment
programs for pregnant women likely limits the positive impact of the law. Furthermore, it was

Although the word “addicted” is used in the Texas legislation, medical experts agree that it is incorrect and
stigmatizing to refer to babies as addicted rather than recognizing they are experiencing transient symptoms unrelated
to any compulsive substance seeking behavior, which is a key component of addiction.
5
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undermined even more significantly by Tennessee’s enactment a year later of the country’s only law
explicitly authorizing punishment of pregnant women for the crime of “fetal assault,” with special
provisions focusing on pregnant women who used opioids. This law, in effect, created a crime of
drug use for only one class of persons in Tennessee – pregnant women. Although the
criminalization law was short-lived (as a result of strong local and national education activism and
investigative media reports, the legislature allowed it to lapse after two years), any attempt to assess
the effect of the Safe Harbor Act would likely be confounded by the later law’s counter-effect. No
other state has yet enacted a law similar to the Safe Harbor Act.

L EGAL S UBSTANCE U SE : A LCOHOL

AND

M ARIJUANA ( IN

SOME STATES )

Laws on reporting alcohol use during pregnancy have been enacted in 36 states, with 32 of them
mandating reporting and 20 of those mandates being linked to child welfare agency referral. As with
laws mandating reporting of drug use during pregnancy, there is substantial protocol variation across
states, with reporting triggered in some states by observation of alcohol-related effects in a newborn
and in others simply by knowledge or beliefs about the behavior of a pregnant woman. For example,
healthcare providers in Arizona are required to report when they believe a newborn “may be
affected by the presence of alcohol,” while in Minnesota there is a mandate to report if a healthcare
or social service provider, other than those providing prenatal and other health services to a
pregnant woman, believes that the woman has consumed alcohol “in any way that is habitual or
excessive” (Seiler, 2016).
As legal restrictions on marijuana use have eased in many states, questions are arising about
appropriate use of THC exposure testing and the consequences of positive results. In Colorado, for
example, where recreational use of marijuana is legally permissible for adults over 21, some hospitals
test infants for THC exposure and state law requires that healthcare providers notify child welfare
authorities of positive test results. The state law on marijuana use does not impose special
restrictions during pregnancy, and there are anecdotal reports that use during pregnancy to treat
nausea is common. This can result in women being reported for actions that are not prohibited.
The Colorado Department of Health & Environment has published guidance for healthcare
providers, advising that patients should be informed during prenatal visits that although marijuana
use is legal in the state for adults over 21, this “doesn’t mean it is safe for pregnant moms or babies.”
The guidance also suggests telling patients that some hospitals test babies after birth for drugs and
that state law requires notification when a baby tests positive for THC at birth (Colorado
Department of Public Health & Environment, 2015).

C RIMINALIZATION , P ROSECUTION ,

AND

D ETENTION

Tennessee is the only state to have enacted a law making drug use during pregnancy a crime, and it
allowed the law to expire in July 2016 only two years after passage. The law sparked widespread
opposition from doctors, women, and advocates who argued that it was dangerous and harmful,
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driving pregnant women away from prenatal care and drug treatment. Although public discussion
largely focused on use of the law to address concerns about NAS, in practice it was also used against
pregnant women who used other drugs, including the first woman charged under the law who tested
positive for methamphetamine, a drug that does not cause NAS. The one woman who is still being
charged under the law was initially charged with attempted murder for trying to end her pregnancy
with a coat hanger.
Even without laws that so explicitly prohibit pregnant women’s drug use, however, states use laws in
other ways that make pregnant women subject to prosecution and punishment over and above what
applies to a non-pregnant person. Investigative journalists examining the topic of drug use during
pregnancy found that at least 45 states have tried to prosecute women for exposing their fetuses to
drugs (Miranda et al., 2015).
While attempts to prosecute women may be uncommon in some states, in others, state officials are
actively working to make such prosecutions standard. In Alabama, as a result of state court rulings,
drug use while pregnant is treated as chemical endangerment of a child, and in South Carolina the
courts have determined that the word “child” in its criminal laws includes viable fetuses, making
every law using that term, including the state’s child endangerment law and its homicide by child
abuse laws, applicable to pregnant women.
In addition, in three states (Minnesota, Oklahoma, and South Dakota) use of certain drugs or
“abuse” of alcohol during pregnancy is grounds for civil commitment, and in Wisconsin being
pregnant and using alcohol or a controlled substance provides a basis for detention or arrest under
state civil child protection laws. Proponents argue these laws are necessary to protect the fetus.
While these women are not initially incarcerated in prison or jail, they may be involuntarily detained
in an inpatient treatment program by order of a court and may face incarceration if they refuse
treatment through contempt proceedings. In Oklahoma and South Dakota, the law gives the state
authority to involuntarily commit a pregnant woman who is “abusing” alcohol to a treatment facility.
In Minnesota, the law includes an early intervention path for mandated treatment up to 90 days and
an option for judicial commitment of 6-12 months; the early intervention option may consist of day
treatment, medical compliance monitoring, and hospitalization up to 21 days (Alcohol Policy
Information System, 2015a). In Wisconsin, the law gives the state authority to detain a woman for
the entire duration of her pregnancy (Miranda et al., 2015).
The rules of civil and criminal procedure allow leeway for courts and child welfare authorities to
serve as a bulwark against scientifically unfounded prosecutions or threats to parental rights, but the
previously discussed review of arrests of and interventions on pregnant women found that in many
cases “the courts failed to act as judicial gatekeepers to ensure, as they are required to do, that
medical and scientific claims are in fact supported by expert testimony based on valid and reliable
scientific evidence” (Paltrow & Flavin, 2013). In the absence of such gatekeeping, reproductive
health, rights, and justice advocates rightly observe that the laws in place today on substance use
during pregnancy threaten the human rights and reproductive autonomy not only of pregnant
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women but also of anyone perceived as having the capacity to get pregnant. In addition, these
policies pose an imminent danger to the health and well-being of infants and children whose care
and family life may be disrupted by the application of policy that runs counter to the scientific
evidence (Paltrow & Flavin, 2013).
In October 2016, the United Nations Working Group on Arbitrary Detention expressed concern
about U.S. policies that permit the confinement of pregnant women suspected of drug or alcohol
use, explaining, “This form of deprivation of liberty is obviously gendered and discriminatory in its
reach and application.” The Working Group urged that such policies be replaced with “alternative
measures that protect women without jeopardizing their liberty” and that federal authorities take
steps to maximize the ability of healthcare. Federal funding, they suggested, could be made
contingent on the elimination of state or local practices that threaten maternal health by authorizing
involuntary detention (United Nations Working Group on Arbitrary Detention, 2016).

R ECENT F EDERAL A CTIONS
Congress recently took up this issue again, driven generally by legislators’ desire to address the
problems associated with increased use of opioids and specifically by a media report on the uneven
application of the federal Child Abuse Prevention and Treatment Act (CAPTA) requirements
around the country (Wilson & Shiffman, 2015). The Comprehensive Addiction and Recovery Act
(CARA), discussed earlier in this section, includes provisions amending CAPTA’s eligibility criteria
so that, in order to receive grants, states must engage in more rigorous monitoring of provider
reporting and referrals of infants determined to be affected by substance use at birth (CARA, 2016).
CARA also added new state reporting mandates, requiring states to produce an annual data report
on how many substance-exposed infants were identified and for how many infants a plan of safe
care was developed. Additionally, it established a more defined oversight role for the U.S.
Department of Health & Human Services (HHS), requiring HHS to ensure that each state’s policies
and procedures meet certain requirements; like CAPTA, CARA directs HHS to issue guidance to
states regarding the requirements and best practices for the development and implementation of
plans of safe care. And, finally, it expanded the law to include infants found to be affected by
alcohol use during pregnancy, a condition that was not addressed when the reporting requirement
was first enacted in 2003.
While women’s health advocates agree that the imprecision of the current CAPTA reporting
requirements created confusion, and the discretion it allowed resulted in policies being applied with
racial and socioeconomic bias (Weber, 2007), the 2016 reforms making the federal requirements
more specific and increasing federal oversight of their application have also sparked concerns.
Noting that the CAPTA provisions have been in place for more than a decade and have never been
evaluated by a formal research study, critics of the new law cautioned against taking steps to enhance
the law’s requirements without first determining the impact of the mandatory reporting approach.
They point to the strong opposition of medical experts to mandated reporting and the body of
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evidence that it undermines the relationship between providers and patients and creates barriers to
high-quality and timely care that are necessary both to protect the health of the pregnant woman and
to promote the health of the infant at birth and beyond.
For all of these reasons, advocates had urged Congress instead to amend the CARA legislation so
that it would: move states toward evidence-based, child-protective, and medically appropriate
policies; discourage states from adopting punitive practices that drive women away from care; ensure
that states are able to provide service referrals for the child and the family without a conclusion that
abuse or neglect has occurred; and require states to report on the location, economic status, and race
of infants identified as affected by maternal substance use so that it is possible to monitor and guard
against any discriminatory application of the law. They further suggested that states should be given
the option of reporting to a state health agency that has a focus on maternal and child health, rather
than to child protective services systems, which conduct investigations into charges of abuse and
neglect and wield the threat of family separation. CARA was signed into law in July 2016, however,
without addressing those recommendations.
Congress has also attempted to address the uncertainties about treatment for women during
pregnancy and for infants by including in legislation a number of directives to mobilize federal
agencies in the effort to assess the evidence, identify gaps in knowledge, and develop resources to
support evidence-based care and treatment. In late 2015, the Protecting Our Infants Act (POIA)
became law, directing HHS to develop a strategy to determine the most appropriate treatment for
pregnant women with opioid use disorders and the most appropriate treatment and management of
infants with NAS (Protecting Our Infants Act, 2015). The agency is working to catalogue what is
known about the long-term effects of prenatal opioid exposure on children, and to develop
recommendations for safely reducing opioid use by pregnant women and treating opioid
dependence and NAS. POIA also authorized CDC to provide technical assistance to states to
improve the availability and quality of data collection and surveillance activities regarding NAS.
In addition, Senator Bob Casey of Pennsylvania has requested that the Government Accountability
Office (GAO) investigate and report on how child welfare agencies are dealing with NAS and on
state compliance with CAPTA reporting requirements. And when CARA was enacted, it directed
the GAO to produce an additional report on NAS, including information on its prevalence in the
United States; Medicaid coverage for treatment of infants with NAS; treatment settings, costs, and
reimbursement methodologies associated with NAS treatment; and best practices for treating infants
with NAS.
In contrast to policy responses that focus on testing, reporting, and punitive measures, these efforts
could create the foundation for an evidence-based policy approach. For example, SAMHSA is
working with a steering committee comprised of representatives from 14 federal agencies to produce
a summary of current research establishing the most appropriate interventions for the treatment of
pregnant and parenting women with opioid use disorder and their infants. In August 2016, they
published a draft of this document, titled Advancing the Care of Pregnant and Parenting Women with Opioid
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Use Disorder and their Infants: A Foundation for Clinical Guidance. They received public comments on the
draft and are expected to produce a final document in 2017.
The 2016 U.S. Surgeon General’s Report Facing Addiction in America identifies pregnant women as a
population that should receive early intervention, which can serve as a bridge between prevention
and treatment services, for problematic substance use. The report explains, “Early intervention
consists of providing information about substance use risks, normal or safe levels of use, and
strategies to quit or cut down on use and use-related risk behaviors, and facilitating patient initiation
and engagement in treatment when needed” (U.S. Department of Health and Human Services, 2016).
Finally, in December 2016 Congress passed and President Obama signed the 21st Century Cures Act,
which includes an authorization of $1 billion for state grants to address opioid use (21st Century
Cures Act, 2016). If Congress includes those dollars in its appropriations, it will result in a
substantial increase in funds available for state efforts. The law states that the grants will be used for
activities that supplement efforts undertaken by state agencies responsible for substance abuse
prevention and treatment. It explicitly notes that this may include “public health-related activities”
such as prescription drug monitoring programs, evaluation to identify effective prevention strategies,
training for healthcare practitioners, and access to healthcare services including treatment programs.
There is, however, no explicit requirement that the needs of pregnant or parenting women be
addressed.

I MPACT

ON

W OMEN

OF

C OLOR

AND

L OW - INCOME W OMEN

Mandatory reporting of positive drug tests to child protective services raises serious equity concerns,
because research has found that cases involving mothers or children of color are referred to child
protective services at higher rates than those involving White children (Ellsworth, Stevens, &
D’Angio, 2010; Osterling, Andrade, & Austin, 2008; Roberts & Nuru-Jeter, 2012). Punitive policies
also disproportionately burden women who use public social and health services, because they are
more likely to be tested and to have positive test results reported to authorities (Stone, 2015).
In a 1990 study using data from Pinellas County, Florida, Chasnoff and colleagues reported Black
women were ten times more likely than White women to be reported to health authorities at
delivery, even though the prevalence of alcohol and drug use was similar at the women’s first
prenatal care visits. To reduce disparities, they proposed universal screening at prenatal care
(Chasnoff et al., 2012). Since then, however, research has cast doubt on the efficacy of such
universal screening to eliminate disparities.
In a 2012 study, Roberts and Nuru-Jeter considered the possible pathways through which universal
screening at prenatal visits might be expected to improve equity. One is to make surveillance more
equitable, which could shrink or eliminate disparities by resulting in more referrals of White women
to child protective services. The other is to use screening as a first step to effective treatment, which
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could result in fewer women using substances later in pregnancy and, consequently, fewer referrals
at delivery. The authors used data from a California county where prenatal care providers serving
Medicaid-covered and privately insured pregnant women conduct universal screening, and tested
these two potential explanations by examining the proportions of White, Black, and Hispanic
women in the following groups: those identified in prenatal care as using substances; those who
entered substance treatment; and those who were referred to CPS at delivery for maternal alcohol or
drug use. One might expect the racial/ethnic breakdown to remain approximately equal at each of
these three points, but Roberts and Nuru-Jeter found that more White than Black women than
expected entered treatment, and more Black infants than expected were reported to CPS. Their
findings show that it is a mistake to assume identification of substance use in prenatal care results in
effective treatment. “Ensuring that women receive treatment and services during pregnancy is a
necessary pre-condition for screening to function as support and not primarily as surveillance,” the
authors conclude (Roberts & Nuru-Jeter, 2012).
Results from the Kaiser Permanente Northern California (KPNC) “Early Start” program suggest
that when universal screening is coupled with integrated substance abuse and prenatal care
treatment, perinatal outcomes may improve. At KPNC, women identified through screening as
being at risk for substance use during pregnancy are referred to an Early Start Specialist in the same
clinic, who conducts an in-depth psychosocial assessment, and receive a brief intervention session.
Based on assessment findings, women are offered counseling or other services along with prenatal
care. Not all women who screened positive received Early Start treatment, the authors note,
explaining that “some patients do not participate in Early Start due to factors such as entering
prenatal care late, scheduling and transportation problems, motivation, issues of fear and potential
stigmatization.” A study of 49,985 female KPNC members who completed screening questionnaires
between 1999 and 2003 found significantly lower rates of neonatal-assisted ventilation, preterm
delivery, and low birthweight in the group that screened positive and received treatment, compared
to the group that screened positive and did not receive treatment. The authors conclude, “Early
Start’s replicable model of integrating substance abuse treatment with prenatal care is cost-effective
and significantly decreases negative birth outcomes as well as maternal morbidity,” (Goler,
Armstrong, Taillac, & Osejo, 2008). However, the fact that a substantial proportion of the members
who screened positive did not receive Early Start treatment (1,359 out of 3,432, or 40%)
demonstrates that screening alone is insufficient for reducing adverse neonatal outcomes. The best
way to reduce disparities in CPS reporting may be to eliminate barriers to treatment use and ensure
effective treatments are available to serve all women in need.
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F UTURE D IRECTIONS
Over many decades, the United States has struggled to identify effective strategies for responding to
problems caused by use of substances from alcohol to marijuana to various forms of cocaine, and
today the public focus of the struggle is concentrated on opioids and methamphetamine use. If the
goal is to achieve the best possible health outcomes for pregnant women and their children, research
clearly demonstrates that punitive approaches have not worked, while public health models that
incorporate harm reduction strategies and ensuring access to appropriate services show promise.
It is important to recognize that, due to the limited and evolving scientific knowledge about prenatal
exposure, much of the policy related to substance use by pregnant women has “been made in a
climate of scientific uncertainty” (Lester et al., 2004). As researchers gain a deeper understanding of
the complex and interacting causes of conditions frequently attributed to prenatal drug and alcohol
exposure, the challenge of establishing a solid evidence base for these laws and policies grows. Yet
the laws are already on the books, and these policies and practices are being applied to pregnant
women in spite of the shaky basis of the underlying science.
To improve SUD treatment options for pregnant women, more research is needed to identify the
most effective treatments, including psychosocial and pharmacological treatments, for pregnant
women who use different substances or substance combinations. Studies should investigate the role
of partners and family-centered interventions, as well as the contributions of Medicaid coverage
expansions to timely receipt of appropriate treatment. Additional research into the long-term effects
of buprenorphine and other pharmacological SUD treatments on fetuses can allow women and their
healthcare providers to make better-informed decisions about treatment options.
While pregnant women who want to reduce or stop substance use should have information about,
and unimpeded access to, effective and affordable treatment programs, future research should not
be limited to treatment. It is also critical to build understanding of how social and economic
conditions contribute to harmful use of alcohol and drugs so that future policies can address those
causes, creating opportunities to intervene upstream. Furthermore, research should investigate
additional factors that make use of alcohol and drugs more harmful to some, including potentially
inadequate nutrition.
In addition, there is a need for further research into the impact of punitive measures on women’s
health and use of care, including quantitative and qualitative research involving different geographic,
racial/ethnic, and socioeconomic groups of women to fill gaps in the current literature.
Despite the primacy of stated concerns for the health and safety of the fetus and of future children,
many laws and policies about substance use by pregnant women do not require actual evidence of
harm, and cases are frequently brought based on claims that the pregnant woman’s behavior created
a risk of harm (Paltrow & Flavin, 2013). As mentioned above, however, associations with negative
outcomes does not always translate into actual harm. And when laws and policies lead to
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interventions by child protective service agencies, “There’s little evidence to suggest that such
interventions result in better outcomes” (National Advocates for Pregnant Women, 2015). In fact,
there is an “extraordinary consensus by public health organizations, medical groups, and experts that
such actions undermine rather than further maternal, fetal, and child health” (Paltrow & Flavin, 2013).
Research over decades by healthcare professionals caring for substance-using pregnant women and
their children shows that even evidence of drug exposure in a newborn is not proof of lasting harm
or proof that the best interests of the child will be served by removing it from parental custody. Just
as studies conducted when crack cocaine use was at its peak showed that, with appropriate support,
children born with cocaine in their systems consistently did better on normal infant development
measures when left with their mothers than when placed in foster care, research today shows that
the best practices for decreasing severity and duration of symptoms experienced by infants exposed
prenatally to opiates who experience neonatal abstinence syndrome is for them to be held and, when
possible, breastfed by mothers (Abrahams et al., 2007; Welle-Strand et al., 2013).
There are some concerns, however, that research to assess opioid use by pregnant women and NAS
in infants holds the potential to increase punitive and criminal actions against pregnant women who
use, or are suspected of using, drugs. Critics point to the experience of Tennessee, which
implemented a NAS monitoring system that was intended to develop health-centered policies and
practices. Although the state Department of Health explicitly rejected punitive responses when it
created the monitoring system, the data collected was ultimately used by the state legislature to
justify enacting a law that criminalized substance use specifically during pregnancy (Sangoi,
Ainsworth, & National Advocates for Pregnant Women, 2015). Developing effective, equitable, and
balanced policies that protect the health and rights of women and their children that are based on
good evidence and data will remain a challenge both to researchers and policymakers.

C ONCLUSION
This paper has explored some of the existing research and current policies regarding substance use
for pregnant and parenting women. It is not meant to be an exhaustive literature review but rather an
overview of current evidence and its impact on policy. Exchange of accurate scientific and clinical
information between researchers and policy-makers has the potential to ensure that policies are
grounded in the best available evidence. Making the connection between policy and science is critical
if we are to promote women’s health through improved access to high-quality healthcare.
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